Activité du CIC : La Recherche

Les missions du CIC

Organisation de la recherche clinique

Enseignement de/par la recherche clinique

Production de connaissances

Le CIC en quelques chiffres

Graphique par spécialité

Activité globale entre 1995 et 2007

Cliquer pour agrandir les images

Les services proposés par le CIC

Développements clinique, technico-réglementaire
Etudes de faisabilité
Data Management
Management d’études cliniques
Implémentation du projet
Management
Monitoring sur site

Explorations au CIC

Investigations cardiovasculaires :

Equipements sur site

Investigations respiratoires
Investigations métaboliques
Investigations troubles du sommeil

Publications scientifiques du CIC 1996 - 2007

Publications dans des revues internationales à comité de lecture
1996

Chati Z, Zannad F, Jeandel C, Lherbier B, Escanye JM, Robert J, Aliot E. Physical deconditioning may be a mechanism for the skeletal muscle energy phosphate metabolism abnormalities in chronic heart failure. Am Heart J 1996;131:560-6

Candiloros H, Zeghari N, Ziegler O, Donner M, Drouin P. Hyperinsulinemia is related to erythrocyte phospholipid composition and membrane fluidity changes in obese non-diabetic women. JCEM, 1996;81:2912-8

Ziegler O, Méjean L, Igau B, Fruchart JC, Drouin P, Fiévet C. Accessibility of human apolipoprotéin B-100 epitopes in insulin-dependent diabetes : relation with the surface lipid environment of atherogenic particles. Diabetes & metabolism, 1996;22:179-84

Khder Y, El Ghawi R, Bray des Boscs L, Aliot E, Zannad F. Investigations of the peripheral vascular mechanisms implicated in congestive heart failure by the non-invasive evaluation of the radial artery compliance and reactivity. Int J Cardiol 1996;56:149-58

Candiloros H, Muller S, Ziegler O, Donner M, Drouin P. Role of albumin glycation on the erythrocyte aggregation : an in vitro study. Diabetic Medicine, 1996;13:646-50

Guerci B, Igau B, Ziegler O, Créa T, Fruchart JC, Drouin P, Fiévet C. Intraperitoneal insulin infusion improves the depletion in choline-containing phospholipids of LpB particles in type I diabetic patients. metabolism;1996:45(4):430-4

Chati Z, Mertès PM, Aliot E, Zannad F. Plasma levels of atrial natriuretic peptide and of other vasoconstricting hormones in patients with chronic heart failure : relationship to exercise capacity. Int J Cardiol 1996;57:135-42

Zannad F. Concomitant diseases in elderly hypertensives. The position of Nicardipine. J Hypertens, 1996;14 (suppl 3):S37-S40

Khder Y, Bray des Boscs L, Jeandel C, Aliot E, Zannad F. Endothelial viscoelastic and sympathetic factors contributing to the arterial wall changes during ageing. Cardiology in the Elderly, 1996;4:161-5

Regis-Bailly A, Visvikis S, Steinmetz J, Feldmann L, Briancon S, Danchin N, Zannad F, Siest G. Frequencies of five genetic polymorphisms in coronarographied patients and effects on lipid levels in a supposed healthy population. Clin Genet 1996;50:339-47

Zannad F, Matzinger A, Larche J. Trough/peak ratios of once daily angiotensin converting enzyme inhibitors and calcium antagonists. Am J Hypertens 1996;9:633-43

1997

Khder Y, Bray des Boscs L, Jeandel C, Aliot E, Zannad F. Effects of blood pressure control on radial artery compliance and distensibility in hypertensive patients. Am J Hypertens, 1997;10:269-74

Muller S, Denet S, Candiloros J, Barrois R, Wiernsperger N, Donner M, Drouin P. Action of metformin on erythrocyte membrane fluidity in vitro and in vivo. Eur J Pharmacol 1997;337/103-110

Igau B, Castro G, Clavey V, Slomianny C, Bresson R, Drouin P, Fruchart JC, Fiévet C. In vivo glucosylated LpA-I subfraction. Evidence for structural and functional alterations. Arterioscler Thromb Vasc Biol 1997, 17:2830-6

Briançon S, Alla F, Mejat E, Guillemin F, Villemot JP, Mertes PM, Zannad F. Mesure de l'incapacité fonctionnelle et de la qualité de vie dans l'insuffisance cardiaque : adaptation transculturelle et validation des questionnaires de Goldman, du Minnesota et de Duke. Arch Mal Coeur Vaisseaux 1997;90:1577-85

1998

Chati Z, Bruntz JF, Ethevenot G, Aliot E, Zannad F. Abnormal transesophageal Doppler coronary flow reserve in patients with dilated cardiomyopathy: relationship to exercise capacity. Clin Science, 1998;94:485-92

Sass C, Zannad F, Herbeth B, Salah D, Chapet O, Siest G, Visvikis S. Apolipoprotein E4, lipoprotein lipase C447 and angiotensin-I converting enzyme deletion alleles were not associated with increased wall thickness of carotid and femoral arteries in healthy subjects from the Stanislas cohort. Atherosclerosis 1998;140:89-95

Adams KF, Zannad F. Clinical definition and epidemiology in advanced heart failure. Am Heart J 1998;135:S204-S215

Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G; Dal Palu C, Hansson L, Magnani B, Rahn KH, Reid J, Rodicio J, Sagar J, Safar M, Eckes L, Ravinetto R on behalf of the ELSA investigators. Risk factors associated with alterations in carotid intima-media thickness in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens 1998;16:949-61

Khder Y, El Ghawi R, Bray Des Boscs L, Meilhac V, Stoltz JF, Aliot E, Zannad F. Calcium antagonist and thiazide diuretic have opposed effects on blood rheology and radial artery compliance in arterial hypertension. A randomly allocated double-blind study. Fund Clin Pharmacol 1998, 12:457-62

Guerci B, Meyer L, Delbachian I, Kolopp M, Ziegler O, Drouin P. Blood glucose control on Sunday in IDDM patients: intensified conventional insulin therapy versus continuous subcutaneous insulin infusion. Diabetes Res Clin Pract 1998,40;175-80

Zannad F, Visvikis S, Gueguen R, Sass C, Chapet O, Herbeth B, Siest G. Genetic strongly determine left and rights carotid arteries wall thickness. Hum Genet 1998;103:183-8

Zannad F, Chati Z, Guest M, Plat F And The Fosinopril In Heart Failure Study Investigators. Differential Effects of fosinopril and enalapril in patients with mild to moderate chronic heart failure. Am Heart J, 1998, 136:672-80

Melki V, Renard E, Lassmann-Vague V, Boivin S, Guerci B, Hanaire-Broutin J, Bringer J, Bélicar P, Jeandidier N, Meyer L, Blin P, Augendre-Ferrante B, Tauber JP. Improvement of HbA1c and blood glucose stability in IDDM patients treated with Lispro insulin analog in external pumps. Diabetes Care 1998;21:977-82

Sass C, Herbeth B, Chapet O, Siest G, Visvikis S, Zannad F. Intima media thickness and diameter of carotid and femoral arteries in children, adolescents and adults from the Stanislas Cohort. Effect of age, sex, anthropometry and blood pressure. J Hypertens, 1998:16;1593-602

Khder Y, Briancon S, Petermann R, Quilliot D, Stoltz Jf, Drouin P, Zannad F. Shear stress abnormalities contribute to endothelial dysfunction in hypertension but not in type II diabetes. J Hypertens, 1998,1619-25

Zannad F. Ambulatory blood pressure monitoring in the evaluation of responses to antihypertensive therapy: advantages and difficulties. J Hypertens 1998;16 (suppl 9):S9-S13

Michel C, Chati Z, Mertès PM, Escanye JM, Zannad F. Physical activity, skeletal muscle beta-adrenoceptor changes and oxidative metabolism in experimental chronic heart failure. Fund Clin Pharmacol 1998;12:263-9

1999

Zannad F, Bernaud C, Fay R for the General Physicians Investigator's Group. Double-blind, randomized, multicentre comparison of the effects of amlodipine and perindopril on 24-h therapeutic coverage and beyond in patients with mild-to-moderate hypertension. J Hypertens, 1999;17:137-46

Zannad F, Briancon S, Juillière Y, Mertes PM, Villemot JP, Alla F, Virion JM and the EPICAL investigators. Incidence, clinical and etiologic features, outcomes and prognostic predictors of advanced chronic heart failure. The EPICAL study. JACC, 1999;33:734-42

Zannad F, Boivin JM and the Lorraine General Physician Investigators Group. Ambulatory 24-hour blood pressure assessment of the felopidine-metoprolol combination vs amlodipine in mild to moderate hypertension. J Hypertens 1999;17:1023-32

Fluckiger L, Boivin JM, Quilliot D, Jeandel C, Zannad F. Differential effects of aging on heart rate variability and blood pressure variability. J Gerontol 1999;54A:B219-B224

Hadjadj S, Paul JL, Meyer L, Durlach V, Vergès B, Ziegler O, Drouin P, Guerci B. Delayed Changes in Postprandial Lipid in Young Normolipidemic Men after a Noctunal Vitamin A Oral Fat Load Test. J Nutr 1999;129:1649-55

Guerci B, Meyer L, Sallé A, Charrié A, Dousser B, Ziegler O, Drouin P. Comparison of metabolic deterioration between Insulin Analog and Regular Insulin after a 5-Hour Interruption of a Continuous Sunbcutaneous Insulin Infusion in Type 1 Diabetic Patients. J Clin Endocrinol metab, 1999;84:2673-8

O'Connor CM, Gattis WA, Zannad F, McNulty SE, Gheorghiade M, Adams KF, Califf RM, McKenna WJ, Soler-Soler J, Swedberg A. Beta-blocker therapy in advanced heart failure : clinical characteristics and long-term outcomes. Eur J Heart Failure 1999;1:81-8

Guerci B, Antebi H, Meyer L, Durlach V, Ziegler O, Nicolas JP, Alcindor LG, Drouin P. Increased ability of LDL from normolipidemic type 2 diabetic women to generate peroxides. Clin Chem 1999;45(9):1439-48

Guerci B, Meyer L, Sommer S, George JL, Drouin P, Angioï-Duprez K. Severity of diabetic retinopathy is linked to lipoprotein (a) in type 1 diabetic patients. Diab metabol 1999;25:412-8

2000

Tang R, Hennig M, Thomasson B, Scherz R, Ravinetto R, Catalini R, Rubba P, Zanchetti A, Bong GM for the ELSA investigators. Baseline reproducibility of B-mode ultrasonic measurement of carotid artery intima-media thickness: The European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens 2000;18:197-201

Guerci B, Vergès B, Durlach V, Hadjadj S, Drouin P, Paul JL. Relationship between altered postprandial lipidemia and insulin resistance in normolipidemic and normoglucose tolerant obese patients. Int J Obesity 2000;24:468-78

Chango A, Boisson F, Barbé F, Quilliot D, Droesch S, Pfister M, Frémont S, Rosenblatt DS, Nicolas JP. The effect of 677C->T and 1298A->C mutations on plasma homocystéine and 5,10-Methylenetetrahydrofolate reductase activity in healthy volunteers. British J Nutr 2000,83;593-6

Saviana B, Quilliot D, Ziegler O, Bigard MA, Drouin P, Guéant JL. Diagnosis of lipid malabsorption in patients with chronic pancreatitis: a new indirect test using protprandial plasma apolipoprotein B-48. Am J Gastroenterol 2000;94:3229-35

Zannad F. The potential advantages of a modern antihypertensive therapy in the elderly. J Cardiovasc Pharmacol 2000;35:S19-S23

Sass C, Pallaud C, Zannad F, Visvikis S. Relationship between E-selectin L/F554 polymorphism and blood pressure in the Stanislas cohort. Hum Genet 2000, 107:58-61

Zannad F. Preserving target-organ function with candesartan cilexetil in patients with hypertension. Blood Press Suppl 2000;8, 36-9

Echemann M, Zannad F, Briançon S, Juillière Y, Mertès PM, Virion JM, Villemot JP and the EPICAL investigators. Determinants of angiotensin-converting enzyme inhibitor prescription in severe heart failure with left ventricular systolic dysfunction: The EPICAL study. Am Heart J 2000;139:624-31

Alla F, Briancon S, Juillière Y, Mertès PM, Villemot JP, Zannad F. Differential clinical prognostic classifications in dilated and ischemic advanced heart failure: the EPICAL study. Am Heart J 2000;139:895-904

Zeghari N, Vidal H, Younsi M, Ziegler O, Drouin P, Donner M. Adipocyte membrane phospholipids and PPAR expression in obese women : relationship to hyperinsulinémia. Am J Physiol Endocrinol metab 2000;279:E736-E743

Zeghari N, Younsi M, Meyer L, Donner P, Drouin M, Ziegler O. Adipocyte and erythrocyte plasma membrane phospholipid composition and hyperinsulinemia : a study in non diabetic and diabetic obese women. Int J Obesity 2000;24:1600-7

Visvikis S, Sass C, Pallaud C, Grow MA, Zannad F, Siest G, Erlich HA, Cheng S. Familial studies in genetics of cardiovascular diseases: the Stanislas Cohort. Clin Chem Lab Med 2000;38:827-32

Guerci B, Hadjadj S, Quilliot D, Ziegler O, Drouin P. No acute response of leptin to an oral fat load in obese patients and during circadian rhythm in healthy controls. Eur J Endocrinol 2000;143:649-55

Zannad F, Alla F Dousset B, Perez A, Pitt B on behalft of the RALES Investigators. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure. Insights from the Randomized ALdactone Evaluation Study (RALES). Circulation 2000;102:2700-6

Vigouroux C, Bourut C, Guerci B, Ziegler O, Magré J, Capeau J, Meyer L. A new missense mutation in the calcium-sensing receptor in familial benign hypercalcaemia associated with partial lipoatrophy and insulin resistance diabetes. Clinical Endocrinology 2000;53:393-8

2001

Farsang C, Kawecka Jaszcz K, Langan J, Meritz F, Zannad F for the multicentre study group. Antihypertensive effects and tolerability of candesartan cilexetil alone and in combination with amlodipine. Clin Drug Invest 2001;21:17-23

Teculescu D, Hannhart B, Cornette A, Montaut-Verient B, Virion JM, Michaely JP. Prevalence of habitual snoring in a sample of french males. Role of "minor" nose-throat abnormalities. Respiration, 2001;68:365-70

Shah MR, Stinnett SS, McNulty SE, Gheorghiade M, Zannad F, Uretsky B, Adams KF Jr, Califf RM, O'Connor CM. Hemodynamics as surrogate endpoints for survival in advanced heart failure : an analysis from FIRST. Am Heart J 2001, 141:908-14

Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J for the Randomized Aldactone Evaluation Study investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17

Boivin JM, Alla F. Essais Cliniques. Rev Prat 2000;50(18):2073-9

Zannad F. Have we jugulated the epidemic of heart failure? One swallow does not make a summer…Eur Heart J 2001;22:188-90

Pallaud C, Sass C, Zannad F, Siest G, Visvikis S. ApoCII, CETP, Fibrinogen and MTHFR are genetic determinants of Carotid Intima Media thickness in supposed healthy men (the Stanislas Cohort). Clin Genet, 2001;59:316-24

Fagnani F, Buteau L, Virion JM, Briançon S, Zannad F. Prise en charge et coût de l'insuffisance cardiaque sévère dans l'étude EPICAL en Lorraine. Thérapie 2001;56:5-10

Pitt B, Williams G, Remme WJ, Martinez F, Lopez-Sendon J, Neaton J, Roniker B, Hurley S, Burns D, Bittman R, Kleiman J. The EPHESUS Trial: Eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Cardiovascular Drugs and Therapy 2001;15:79-87

Quilliot D, Dousset B, Guerci B, Dubois F, Drouin P, Ziegler O. Evidence that diabetes mellitus favors impaired metabolism of zinc, copper and selenium in chronic pancreatitis. Pancreas 2001;22:299-306

Mayeux L, Teculescu D, Montaut Verient B, Virion JM, Michaely JP, Hannhart B. Occupational status and sleep-disordered breathing in a sample of French males. Eur J Epidemiol 2001;17:71-5

Zannad F, Echemann M, Briançon S, Juillière Y, Mertes PM, Villemot JP, Alla F, Virion JM for the EPICAL investigators. Outcomes in advanced chronic heart failure. Cardiology Review 2001;18:40-3

Teculescu D, Montaut-Vérient B, Hannhart B, Virion JM, Cornette A, Michaely JP. Breathing pauses during sleep: can a non-invasive ENT examination help identify subjects at risk in epidemiological settings? Medical Hypotheses 2001;56(6),653-6

Zannad F, Pletan Y et les participants de la Table Ronde n° 2 Rencontres Nationales de Pharmacologie Clinique, Giens, Septembre 2000. Difficultés à la réalisation des essais cliniques en France. Thérapie 2001;56:341-7

Pallaud C, Sass C, Zannad F, Siest G, Visvikis S. L'apo C3, la CETP, le beta-fibrinogène et la MTHFR sont des déterminants génétiques de l'épaisseur intima-media de la carotide (cohorte Stanislas). Arch Mal Cœur Vaiss 2001;94:851-4

Zannad F, Sass C, Visvikis S. Environmental and genetic determinants of intima media thickness of the carotid artery. Clin Exp Pharmacol Physiol 2001;28:1007-10

Sass C, Pallaud C, Zannad F, Visvikis S. Association entre le polymorphisme Leu554Phe de la E-sélectine et de la pression artérielle au sein de la cohorte Stanislas. Arch Mal Cœur Vaiss 2001;94:855-8

Quilliot D Fluckiger L, Zannad F, Drouin P, Ziegler O. Impaired autonomic control of heart rate and blood pressure in obesity: role of age and of insulin resistance. Clin Auton Res 2001;11:79-86

Zannad F, Dousset B, Alla F. Treatment of congestive heart failure. Interfering the aldosterone cardiac extracellular matrix relationship. Hypertension 2001;38:1227-32

Guerci B, Kearney-Schwartz A, Böhme P, Zannad F, Drouin P. Endothelial dysfunction and type 2 diabetes. Part 1: physiology and methods for exploring the endothelial function. Diabetes metab 2001;17:425-34

Guerci B, Böhme P, Kearney-Schwartz A, Zannad F, Drouin P. Endothelial dysfunction and type 2 diabetes. Part 2: altered endothelil function and the effects of treatments in type 2 diabetes mellitus. Diabetes metab 2001;17:436-47

Quilliot D, Walters E, Guerci B, Fruchart JC, Duriez P, Drouin P, Ziegler O. Effect of the inflammation, chronic hyperglycemia, or malabsorption on the apoliporptoein A-IV concentration in type 1 diabetes mellitus and in diabetes secondary to chronic pancreatitis. metabolism 2001;50:1019-24

Lefrandt JD, Heitman J, Sevre K, Castellano M, Hausberg M, Fallon M, Fluckiger L, Urbigkeit A, Rostrup M, Agabiti-Rosei E, et al. The effects of dihydropyridine and phenylalkylamine calcium antagonist classes on autonomic function in hypertension: the VAMPHYRE study. Am J Hypertens 2001;14:1083-9

Lefrandt JD, Heitman J, Sevre K, Castellano M, Hausberg M, Fallon M, Urbigkeit A, Rostrup M, Agabiti-Rosei E, et al. Contrasting effects of verapamil and amlodipine on cardiovascular stress responses in hypertension. Br J Clin Pharmacol 2001;52:687-92

Guerci B, Paul JL, Hadjadi S, Durlach V, Verges B, Attia N, Girard-Globa A, Drouin P. Analysis of the postprandial lipid matabolism : use of a 3-point test. Diabetes metab 2001 ; 27 : 449-57

Verges B, Guerci B, Durlach V, Galland-Jos C, Paul JL, LaGrost L, Gambert P. Increased plasma apoA-IV level is a marker of abnormal postprandial lipemia: study in normaponderal and obese subjects. Journal of Lipid Research 2001;42:201-9

Clinard F, Bardou M, Sgro C, Lefèvre N, Raphael F, Paille F, Dumas M, Hillon P, Bonithon-Kopp C. Non-steroidal anti-inflammatory and cytoprotective drug co-prescription in general pratice. Eur J Pharmacol 2001,57:737-43

Girerd X, Radauceanu A, Achard JM, Fourcade J, Tournier B, Brillet G, Silhol F, Hano O. Evaluation of patient compliance among hypertensive patients treated by specialists. Arch Mal Coeur Vaiss. 2001,94(8):839-42

2002

Zanchetti A, Gene Bond M, Hennig M, Neiss A, Mancia G, Dal Palù C, Hansson L, Magnani B, Rahn KH, Reid JL, Rodicio J, Safar M, Eckes L, Rizzini P, on behalf of the ELSA investigators. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis. Circulation 2002;106:2422-7

Zannad F, Gille B, Grentzinger A, Bruntz JF, Hammadi M, Boivin JM, Hanotin C, Igau B, Drouin P. The effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. Am Heart J, 2002 Sept;144(3):508-15

Breithardt G, Zannad F, Adragao P. Foreword.

Zannad F. Evidence-based drug therapy for chronic heart failure. Eur Heart J 2002, 4, supp D, D66-D72

Zannad F. Case study: optimization of therapy in chronic heart failure. Eur Heart J 2002, 4, supp D, D131

Alla F, Briançon S, Guillemin F, Juilliere Y, Mertes PM, Villemot JP, Zannad F, for the EPICAL investigators. Self-rating of quality of life provides additional prognostic information in heart failure. Insights into the EPICAL study. Eur J Heart Failure,2002,4(3):337-43

Younsi M, Quilliot D, Al-Makdissy N, Delbachian I, Drouin P, Donner M, Ziegler O. Erythrocyte membrane phospholipid composition is related to hyperinsulinemia in obese non diabetic women : effects of weight loss. metabolism 2002, 51 (10):1261-8

Hanon O, Mounier-Vehier Cl, Fauvel J-P, Marquand A, Jaboureck O, Justin E-P, Kearney-Schwartz A, Girerd X. Trouble de la sexualité chez les hypertendus traités. Arch Mal Cœur Vaiss 2002;95:673-7

Meyer L, Bohme Ph, Delbechian I, Lehert Ph, Cugnardey N, Drouin P, Guerci B. The benefits of Metformin therapy during continous subcutaneous insulin infusion treatment of type 1 diabetic patients. Diabetes Care 2002, 25:2153-8

Thilly N, Briançon S, Juillère Y, Dufay E, Zannad F. Angiotensin-converting enzyme inhibitors in congestive heart failure: practice versus guidelines. J Pharm Technol 2002;18:229-40

Radauceanu A, Virion JM, Boivin JM, Zannad F and the CIC General Practitioners Investigators' Group. Profile of antihypertensive agents assessed with trough/peak ratio, smoothness index and dose omission: an ambulatory blood pressure monitoring study with trandolapril vs quinalpril. Fund Clin Pharmacol 2002, 16:545-54

Zannad F, Kessler M, Grunfeld JP, Thuilliez Ch. Fosidial: a randomised placebo controlled trial of the effects of Fosinopril on cardiovascular morbidity in haemodialysis patients. Study design and patients’baseline characteristics. Fund Clin Pharmacol 2002, 16:353-60

Ogier V, Ziegler O, Mejean L, Nicolas JP, Stricker-Kongrad A. Obesity is associated with decreasing levels of the circulating soluble leptin receptor in humans. Int J Obes Relat metab Disord 2002, 26:(4)496-503

Bohadana AB, Hannhart B, Teculescu DB. Nocturnal worsening of asthma and sleep-disordered breathing. J Asthma 2002, 39(2):85-100

Teculescu D, Hannhart B, Aubry C, Montaut-Verient B, Virion JM, Michaely JP, Gueguen R. Who are the “occasional” snorers? Chest 2002, 122(2):562-8

Echemann M, Alla F, Briançon S, Juillière Y, Virion JM, Mertes PM, Villemot JP, Zannad F on behalf of the EPICAL Investigators. Antithrombotic therapy is associated with better survival in patients with severe heart failure and left ventricular systolic dysfunction (EPICAL STUDY). Eur J Heart Failure 2002, 4:647-54

Robaux S, Bouaziz H, Cornet C, Boivin JM, Lefevre N, Laxenaire MC. Acute postoperative pain management at home after ambulatory surgery: a French pilot survey of general practitioners's views. Anesth analg. 2002,95(5):1258-62

2003

Quilliot D, Walters E, Böhme Ph, Lacroix B, Bonte J.P, Fruchart J.C, Drouin P, Duriez P, Ziegler O. Fatty acid abnormalities in chronic pancreatitis: effect of concomitant diabetes mellitus. Eur J Clin Nutr 2003, 57(3):496-503

Guerci B, Floriot M, Böhme Ph, Durain D, Benichou M, Jelliman S, Drouin P. Clinical performance of CGMS in type 1 diabetic patients treated by continuous subcutaneous insulin infusion using insulin analogs. Diabetes Care 2003, 26(3):582-9

Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, for the Eplerenone Post-AMI Heart Failure Efficacy and Survival Study Investigators. A Clinical Trial of Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunctionafter Myocardial Infarction. New England Journal of Medicine 2003, 348:1309-21

Zannad F, Benetos A. Genetics of Intima Media Thickness. Current Opinion in Lipidology 2003,14(2):191-200

Guerci B, Benichou M, Floriot M, Bohme Ph, Fougnot S, Franck P, Drouin P. Accuracy of an electrochemical sensor for measuring capillary blood ketones by fingerstick samples during metabolic deterioration after continous subcutaneous insulin infusion interruption in type 1 diabetic patients. Diabetes Care 2003, 26(4): 1137-41

Zannad F, Radauceanu A, Parati G. Trough-to-peak ratio, smoothness index and morning-to-evening ratio: why, which and when? J Hypertens 2003,21(5):851-4

Meyer L, Guerci B. Metformin and Insulin in type 1 Diabetes: the 1st step. Diabetes Care 2003, 26(5):1655-6

PGuerci B. La variabilité glycémique asymptomatique : comment l’évaluer et quelle est son incidence clinique? Diabetes Care 2003,29:179-88

Pletan Y, Zannad F, Jaillon P et les participants de la Table Ronde N°1 Giens XV. Information du public sur les essais cliniques et la recherche. Thérapie 2003, 58(3):185-96

Marie PY, Mercennier Ch, Danchin N, Djaballah K, Grentzinger A, Zannad F, Olivier P, Djaballah W, Karcher G, Virion JM, Bertrand A. Residual exercise SPECT ischemia on treatment is a main determinant of outcome in patients with coronary artery disease treated medically at long-term with beta-blockers. J Nucl Cardiol 2003,10(4):361-8

Thilly N, Brainçon S, Juillière Y, Dufay E, Zannad F. Improving ACE inhibitor use in patients hospitalized with systolic heart failure: a cluster randomized controlled trial of clinical practice guideline development and use. J Eval Pract 2003,9(3):373-82

Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, Kleiman J, Klause S, Burnes D, Williams GH. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003,108(15): 1831-8

Marie, P, Mertes PM, Hassan-Sebbag N, De Talance N, Djaballah K, Djaballah W, Friberg J, Olivier P, Karcher G, Zannad F, Bertrand A. Exercise-Release of cardiac Natriuretic Peptides is Markedly Enhanced when Patients with coronary artery disease are treated Medically by Beta Blockers. J Am Coll Cardiol 2004, 43(3) :353-9

Teculescu D, Guillemin F, Virion JM, Aubry C, Hannhart B, Michaely JP, Gueguen R. Reliability of the Wisconsin sleep questionnaire: A French contribution to international validation. Journal of Clinical Epidemiology 2003, 56:436-40

Pletan Y, Zannad F, Jaillon P and the participants in Round Table N°1 Giens XVIII. Public information about clinical trials and research. Thérapie 2003,58(3):197-208

Thilly N, Zannad F, Dufay E, Juillière Y, Briançon S. Elaboration de recommandations de pratique clinique: les inhibiteurs de l’enzyme de conversion dans l’insuffisance cardiaque. Thérapie 2003,58(3):341-9

Andrejak M, Zannad F, Laville M, Duru G, Mourad JJ, Waeber B. Evaluation of different approaches to the treatment of arterial hypertension: combination treatment with low dose perindopril/indapamide versus sequential treatment of stepped-dose treatment. Therapie 2003, 58(4):351-2

2004

Simon T, Boutouyrie P, Gompel A, Christin-Maitre S, Laurent S, Thuillez C, Zannad F, Bernaud C, Jaillon P; The CASHMERE investigators. Rationale, design and methods of the CASHMERE study. Fundam Clin Pharmacol 2004;18(1):131-8

Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, Djian J, Drexler H, Feldman A, Kober L, Krum H, Liu P, Nieminen M, Tavazzi L, Van Veldhuisen DJ, Waldenstrom A, Warren M, Westheim A, Zannad F, Fleming T. Targeted Anticytokine Therapy in Patients With Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004;109:1594-602

Remme W, Boccanelli A, Cline C, Cohen-Solal A, Dietz R, Hobbs R, Keukelaar K, Sendon JL, Macarie C, McMurray J, Rauch B, Ruzyllo W, Zannad F. Increasing awareness and perception of heart failure in Europe and improving care-rationale and design of the SHAPE study. Cardiovasc Drugs Ther 2004;18(2):153-9

Claudot F, Alla F, Essevaz-Roulet M. Aspects éthiques et réglementaires de la recherche en épidémiologie clinique. Le cadre général actuel et ses évolutions. Rev Epidemiol Santé Publique 2004,52:189-203

Zannad F. Efficacité comparée des trois stratégies antihypertensives recommandées en Europe. Am J Cardiovasc Drugs 2004,4(1):13-14

A. Radauceanu, JM Boivin, C. Bernaud, R. Fay, F. Zannad and the CIC General Practitioners Investigators’ Group. Differential time effect profiles of amlodipine, as compared to valsartan, revealed by ambulatory blood pressure monitoring, self blood pressure measurements and dose omission protocol. Fundamental and Clinical Pharmacology 2004;18: 483-91

M. Fouchard, F. Zannad and participants in round table n°4. The results of major clinical trials. Critical assessment, the circulation of information and media coverage. Thérapie 2004,59(3) 323-8

M. Fouchard, F. Zannad et les participants de la table ronde n°4 de Giens XIX. Lecture critique, évaluation, valorisation, information sur les résultats des grands essais cliniques. Thérapie 2004,59(3) 317-22

Mourad JJ, Waeber B, Zannad F, Laville M, Duru G, Andréjak M on behalf of the investigators of the STRATHE trial. Comparison of different therapeutic strategies in hypertension: a low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped-care approach. J Hypertens 2004,22:2379-86

Morgan JM, Marco J, Stockx L, Zannad F. Educational governance for the regulation of industry-sponsored continuing medical education in interventional and device-based therapies. Heart J 2004, 91(6):710-2

Aupetit JF, Senac JP, Latini R, Zannad F. The artery and the myocardium, two post-infarction targets. Presse Med 2004,33(16):1135-6

Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Desvarieux M, Ebrahim S, Fatar M, Hernandez Hernandez R, Kowatnor S, Prati P, Rundek T, Taylor A, Bornstein N, Csiba L, Vicaut E, Woo KS, Zannad F. Mannheim Intima-Media Thickness Consensus. On behalf of the Advisory Board of the 3rd Watching the Risk Symposium 2004, 13th European Stroke Conference, Mannheim, Germany, May 14, 2004. Cerebrovasc Dis. 2004,18(4):346-49

Shah R, Darne B, Atar D, Abadie E, Adams KF, Zannad F; on behalf of the participants in the 5th Cardiovascular Clinical Trialists Workshop. Pharmacogenomics in cardiovascular clinical trials. Fundam Clin Pharmacol 2004,18(6):705-8

Cracowski JL, Yaici A, Sitbon O, Reynaud-Gaubert M, Renversez JC, Pison C, Faure P, Cracowski C, Chouri N, Chaouat A, Chabot F, Schwekhelm E, Maas R, Degano B, Mornex JF, Humbert M. Evaluation pronostique de biomarqueurs dans l’hypertension artérielle pulmonaire. Justification et plan expérimental. Rev Mal Respir 2004,21:1137-43

Ayalew A, Maskali F, Audonnet S, Marie PY, Menu P, Mertes PM, Olivier P, Franck P, Zannad F, Karcher G, Bertrand A. Low-flow ischaemia has no deleterious effect on the steady-state kinetics of 201T1 and 99mTc sestamibi within myocardial tissue. Nucl Med Commun 2004;25(5):475-8

Teculescu D, Hannhart B, Virion JM, Montaut-Verient B, Michaely JP. Marital status and sleep-disordered breathing in a sample of middle-aged french men. Lung 2004,182:355-62

Thuillez C, Zannad F. L’essentiel de 2003 dans l’hypertension artérielle. Arch Mal Cœur Vaiss 2004,97(I) :39-40

2005

Zanetti L, Essevaz-Roulet M, Lefevre N, Radauceanu A, Fay R, Zannad F. Evaluation de la performance d’un outil d’assurance qualité des protocoles institutionnels. Thérapie 2005,60(6):527-37

Ducki C, Rose A, Radauceanu A, Zannad F. Proposition d’un Outil de transmission au patient des Résultats Globaux de la Recherche Biomédicale. Transmission des Résultats Globaux. Thérapie 2005,60(6):545-51

Zannad F. Acute heart failure syndromes: the « Cinderella » of heart failure research. Eur Heart J Suppl 2005, 7(suppl B):B8-B12

Gheorghiade M, Zannad F. Modern management of acute heart failure syndromes. Eur Heart J Suppl 2005, 7(suppl B):B3-B7

Gheorghiade M, Orlandi C, Burnett Jr JC, Demets D, Grinfeld L, Maggioni A, Swedberg K, Udelson JE, Zannad F, Zimmer C, Konstam MA. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of vasopressin antagonism in heart failure: outcome study with tolvaptan (EVEREST). J Card Fail 2005,11(4):260-9

Morgan JM, Marco J, Stockx L, Zannad F. Educational governance for the regulation of industry sponsored continuing medical education in interventional and device based therapies. Heart 2005;91:710-2

Quilliot D, Walters E, Bonte JP, Fruchart JC, Duriez P, Ziegler O. Diabetes mellitus worsens antioxidant status in patients with chronic pancreatitis. American Journal of Clinical Nutrition 2005;81(5):1117-25

Fellstrom B, Zannad F, Schmieder R, Holdaas H, Jardine A, Rose H, Wilpshaar W on behalf of the AURORA study group. Effect of rosuvastatine on outcomes in chronic haemodialysis patients – design and rationale of the AURORA study. Curr Control Trials Cardiovasc Med. 2005;6(1):9

Zannad F, Radauceanu A. Effect of mineralocorticoid receptor blockade on collagen formation and cardiovascular disease with a specific emphasis on heart failure. Heart Failure Reviews 2005,10:71-8

Quilliot D, Zannad F, Ziegler O. Impaired response of cardiac autonomic nervous system to glucose load in severe obesity. metabolism 2005,54:966-74

Paris A, Cracowski JL, Maison P, Radauceanu A, Cornu C, Hommel M. Impact of French «Comité de Protection des Personnes» on the readability of informed consent documents (ICD) in biomedical research : more information, but not better information. Fundam Clin Pharmacol 2005,19:395-9

Guerci B. Glitazones clinical data: an update. Ann Endocrinol 2005,66:1S45-1S58

Ruilope LM, Agabati-Rosei E, Bakris GL, Mancia G, Poulter NR, Taddei S, Unger Th, Volpe M, Waeber B, Zannad F. Angiotensin receptor blockers: Therapeutic targets and cardiovascular protection. Blood Pressure 2005, 14(4):196-209

Pitt B. White H, Nicolau J, Martinez F, Gheorghiade M, Aschermann M, Van Veldhuisen DJ, Zannad F, Krum H, Mukherjee R, Vincent J for the EPHESUS Investigators. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. JACC 2005,46(3):425-31

Quilliot D, Alla F, Bohme P, Bruntz JF, Hammadi M, Dousset B, Ziegler O, Zannad F. Myocardial collagen turnover in normotensive obese patients: relation to insulin resistance. International Journal of Obesity 2005, 29:1321-8

Remme WJ, McMurray JJ, Rauch B, Zannad F, Keukelaar K, Cohen-Solal A, Lopez-Sendon J, Hobbs FD, Grobbee DE, Boccanelli A, Cline C, Macarie C, Dietz R, Ruzyllo W. Public awareness of heart failure in Europe: first results from SHAPE. Eur Heart J 2005, 26:2413-21

2006

Alla F, Kearney-Schwartz A, Radauceanu A, Das Dores S, Dousset B, Zannad F. Early changes in serum markers of cardiac extra-cellular matrix turnover in patients with uncomplicated hypertension and type II diabetes. Eur J Heart Fail 2006,8:147-53

White HD, Aylward Ph, Huang Z, Dalby AJ, Weaver D, Barvik S, Marin-Neto JA, Murin J, Nordlander RO, Van Gilst WH, Zannad F, McMurray J, Califf RM, Pfeffer MA, for the VALIANT investigators. Mortality and morbidity remain high despite captopril and/or valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction. Results from the valsartan in acute myocardial infarction trial (VALIANT). Circulation 2005, 112:3391-9

Zannad F. Managing hypertension: a question of STRATHE. Journal of Human Hypertension 2005,19:S3-S7

Gheorghiade M, Zannad F, Sopko G, Klein L, Pina IL, Konstam MA, Massie BM, Roland E, Tragum S, Collins SP, Filippatos G, Tavazzi L for the International Working Group on Acute Heart Failure Syndromes. Acute heart failure syndromes: current state and framework for future research. Circulation 2005, 112:3358-68

Benetos A, Gardner JP, Kimura M, Labat C, Nzietchueng R, Dousset B, Zannad F, Lacolley P, Aviv A. Aldosterone and telomere length in white blood cells. J Gerontol A Biol Sci Med Sci 2005,60(12):1593-6

Zannad F, Mebazaa A, Juillière Y, Cohen-Solal A, Guize L, Alla F, Rougé P, Blin P, Barlet MH, Paolozzi L, Vincent C, Desnos M, Samii K for the EFICA investigators. Clinical profile, contemporary management and one-year mortality in patients with severe acute heart failure syndromes: The EFICA study. Eur J Heart Fail 2006, 8:697-705

Haffner SM, Ruilope L, Dahlof B, Abadie E, Kupfer S, Zannad F. metabolic syndrome, new onset diabetes and new endpoints in cardiovascular trials. J Card Pharmacol 2006,47(3):469-75

Paris A, Cornu C, Auquier P, Maison P, Radauceanu A, Brandt C, Salvat-Melis M, Hommel M, Cracowski JL. French adaptation and preliminary validation of a questionnaire to evaluate understanding of informed consent documents in phase I biomedical research. Fund Clin Pharmacol 2006,20:97-104

Pitt B, Gheorghiade M, Zannad F, Anderson JL, Van Veldhuisen DJ, Parkhomenko A, Corbalan R, Klug EQ, Mukherjee R, Solomon H, on behalf of the EPHESUS investigators. Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction Eur J Heart Fail 2006, 8:295-301

Kober L, Swedberg K, McMurray JJ, Pfeffer MA, Velazquez EJ, Diaz R, Maggioni AP, Mareev V, Opolski G, Van de Werf F, Zannad F, Ertl G, Solomon SD, Zelenkofske S, Rouleau JL, Leimberger JD, Califf RM. Previously known and newly diagnosed atrial fibrillation. A major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction. Eur J Heart Fail 2006, 8(6):591-8

Sleight P, Pouleur H, Zannad F. Benefits, challenges, and registerability of the polypill. Eur Heart J 2006, 27(14):1651-6

Greenberg B, Zannad F, Pitt B. The role of aldosterone blockade in the future of heart failure treatment post-acute myocardial infarction and beyond. Am J Cardiol 2006, ;97(10A):34F-40F

Zannad F, Kessler M, Lehert P, Grunfeld JP, Thuilliez C, Leizerovicz A, Lechat P. Prevention of cardiovascular events in end stage renal disease: results of a randomized trial of Fosinopril and implications for future studies. Kidney International 2006, 70(7):1318-24

Zannad F, Adamopoulos C, Mebazaa A, Gheorghiade M. The challenge of acute heart failure. Heart Failure Review 2006, 11(2):135-9

Zannad F, Bousquet P, Gothert M. Editorial. Fundam Clin Pharmacol 2006,20(4):337

Boivin JM, Rousseau S, Fay R, Radauceanu A, Zannad F. Utilisation de l’automesure tensionnelle par les médecins généralistes français dans la prise en charge des patients hypertendus. Etude MEGAMET (MEdecins Généralistes et Auto-Mesure Tensionnelle). Arch Mal Cœur Vaiss 2006, 99(7-8)

Guerci B. Acute complications of insulin pump therapy. Diabetes Res Clin Pract 2006,74(Suppl2):S104-7

Karalliedde J, Buckingham R, Starkie M, Lorand D, Stewart M, Viberti G, for the Rosiglitazone Fluid Retention Study Group. Effet of various diuretic treatments on rosiglitazone-induced fluid retention. J Am Soc Nephrol 2006,17:3482-3490

2007

Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, Csiba L; Desvarieux M, Ebrahim S, Fatar M, Hernandez Hernandez R, Jaff M, Kownator S, Prati P, Rundek T, Sitzer M, Schminke U, Tardif JC, Taylor A, Vicaut E, Woo KS, Zannad F, Zureik M. Mannheim Carotid Intima-Media Thickness Consensus (2004-2006). Cerebrovasc Dis, 2007, 14;23(1):75-80

Maggioni AP, Darne B, Atar D, Abadie E, Pitt B, Zannad F. FDA and CPMP rulings on subgroup analyses. Cardiology 2007;107:97-102

Zannad F, Huvelle E, Dickstein K, van Veldhuisen KJ, Stellbrink C, Kober L, Cazeau S, Ritter P, Maggioni AP, Ferrari R, Lechat P. Left bundle branch block as a risk factor for progression to heart failure. Eur J Heart Fail 2007, 9(1):7-14

Weber F, Fay R, Monin P, Boivin JM. Prise en charge de la fièvre de l’enfant. Les connaissances et pratiques des parents sont-elles satisfaisantes ? Archives de Pédiatrie 2007,14:322-9

Radauceanu A, Moulin F, Djaballah W, Marie PY, Alla F, Dousset B, Virion JM, Capiaumont J, Karcher G, Aliot E, Zannad F. Residual stress ischaemia is associated with blook markers of myocardial structural remodelling. Eur J Heart Fail 2007,9:370-6

Tobe S, Kawecka-Jaszcz K, Zannad F, Vetrovec G, Patni R, Shi H. Amlodipine added to Quinapril vs Quinapril alone for the treatment of hypertension in diabetes : The Amlodipine in Diabetes (ANDI) Trial. J Clin Hypertens 2007,9;2:120-7

Zannad F. Aldosterone antagonist therapy in resistant hypertension. J of Hypertens 2007,25:747-50

Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C. Short-term Clinical Effects of Tolvaptan, an Oral Vasopressin Antagonist, in Patients Hospitalized for Heart Failure: The EVEREST Clinical Status Trials. JAMA 2007,297(12):1332-43

Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C. Effects of oral Tolvaptan in patients hospitalized for worsening Heart Failure: the EVEREST outcome trial. JAMA 2007, 297(12):1319-31

Lewis RM, Gordon D, Poole-Wilson PA, Zannad F. Similarities and differences in Design Considerations for Cell Therapy and pharmacologic Clinical Trials, Cardiology 2007;110:73-80

Zannad F, Fay R. Blood pressure-lowering efficacy of olmesartan relative to other angiotensin II receptor antagonists: an overview of randomized controlled studies. Fund Clin Pharmacol 2007,21:181-90

Zannad F. Benefits of First-Line Combination of Perindopril and Indapamide in Clinical Practice for Patients With Hypertension and Diabetes Am J Hypertens 2007,20(7, suppl1): S9-S14

Alla F, Zannad F, Filippatos G. Epidemiology of acute heart failure syndromes. Heart Fail Rev 2007, 12(2):91-5

Filippatos G, Zannad F. An introduction to acute heart failure syndromes: definition and classification. Heart Fail Rev. 2007, 12(2):87-90

Ahmed A, Zannad F, Love TE, Tallaj J, Gheorghiade M, Ekundayo OJ, Pitt B. A propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failure. Eur Heart J 2007,28:1334–1343

Blangy H, Sadoul N, Dousset B, Radauceanu A, Fay R, Aliot E, Zannad F. Serum BNP, hs-C-reactive protein, procollagen to assess the risk of ventricular tachycardia in ICD recipients after myocardial infarction. Europace 2007, 9(9):724-9

Adamopoulos C, Zannad F, Fay R, Mebazaa A, Cohen-Solal A, Guize L, Juillière Y, Alla F. Ejection fraction and blood pressure: equally powerful and interactive predictors of 4-week mortality in severe acute heart failure. Eur J Heart Fai 2007,9(9):935-941

Kessler M, Zannad F, Lehert P, Pierre Grunfeld J, Thuilliez C, Leizorovicz A, Lechat P, for the FOSIDIAL Investigators. Predictors of cardiovascular events in patients with end-stage renal disease: an analysis from the fosinopril in dialysis study. Nephrol Dial Transplant 2007, in press

Borer JS, Pouleur H, Abadie E, Follath F, Wittes J, Pfeffer MA, Pitt B, Zannad F. Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval. Eur Heart J 2007, 28(15):1904-9

Kearney-Schwartz A, Virion JM, Stoltz JF, Drouin P, Zannad F. Haemorheological disturbances in hypertensive type 2 diabetic patients – influence of antihypertensive therapy. Fund Clin Pharmacol 2007, 21(4):387-396

Rajagopalan S, Zannad F, Radauceanu A, Glazer R, Jia Y, Prescott MF, Kariisa M, Pitt B. Effects of valsartan alone versus valsartan/simvastatin combination on ambulatory blood pressure, C-reactive protein, lipoproteins, and monocyte chemoattractant protein-1 in patients with hyperlipidemia and hypertension. Am J Cardiol 2007 100(2):222-6

Sui X, Gheorghiade M, Zannad F, Young JB, Ahmed A. A Propensity Matched Study of the Association of Education and Outcomes in Chronic Heart Failure. Int J Cardiol 2007, in press

Stough WG, Zannad F, Pitt B, Goldstein S. Globalization of cardiovascular clinical research: the balance between meeting medical needs and maintaining scientific standards. Am Heart J 2007,154(2):232-8

Fellstrom B, Holdaas H, Jardine AG, Rose H, Schmieder R, Wilpshaar W, Zannad F. Effect of Rosuvastatin on Outcomes in Chronic Haemodialysis Patients: Patients Baseline Data from the AURORA Study. Kidney Blood Press Res 2007,30(5):314-322

Constans J, Germain C, Gosse Ph, Taillard J, Tiev K, Delevaux I, Mouthon L, Schmidt C, Granel F, Soria P, Lifermann F, Etienne G, Bonnet F, Zoulim K, Farge-Bancel D, Marie I, Allanore Y, Cabane J, Amonchot A, Macquin-Mavier I, Saves M, Zannad F, Conri C and the ERAMS investigators. Arterial stiffness predicts severe progression in systemic sclerosis: the ERAMS study? J Hypertens 2007,9:1900-1906

Teculescu D, Benamghar L, Hannhart B, Montaut-Verient B, Michaely JP. Habitual snoring. Prevalence and risk factors in a sample of the French male population. Rev Mal Respir. 2007 Mar;24(3 Pt 1):281-7

Bousquet P, Zannad F, Atar D. FCP welcomes Cardiovascular Pharmacology and Drug Therapy. Fundam Clin Pharmacol. 2007,21(5):457

Mebazaa A, Gheorghiade M, Piña IL, Harjola VP, Hollenberg SM, Follath F, Rhodes A, Plaisance P, Roland E, Nieminen M, Komajda M, Parkhomenko A, Masip J, Zannad F, Filippatos G. Practical Recommendations For Pre-Hospital and Early In-Hospital Management of Patients Presenting with Acute Heart Failure Syndromes. Critical Care Medicine 2008, in press

Quilliot D, Böhme P, Zannad F, Ziegler O. Sympathetic-leptin relationship in obesity: effect of weight loss. metabolisme, in press

Présentations à des congrès nationaux et internationaux
1996

Khder Y, Bray des Boscs L, Jeandel C, Zannad F. Radial artery structural and functional changes during ageing. XVI Scientific Meeting of the International Society of Hypertension, Glasgow, June 23-27, 1996. J Hypertens 1996;14:S92

Khder Y, Bray des Boscs L, Zannad F. Cold pressor test decreases radial artery compliance and distensibility in healthy control subjects. XVI Scientific Meeting of the International Society of Hypertension, Glasgow, June 23-27, 1996. J Hypertens 1996;14:S92

Khder Y, Zannad F. Attenuated vascular response to cold pressor test in congestive heart failure. Congress of the European Society of Cardiology, Birmingham, August 25-29, 1996 (poster). Eur Heart J, 1996, Volume 17, Supplement

Khder Y, Zannad F. Vascular effects of aldosterone in congestive heart failure. Congress of the European Society of Cardiology, Birmingham, August 25-29, 1996. Eur Heart J, 1996, Volume 17, Supplement

Khder Y, Petermann R, Drouin P, Stoltz JF, Zannad F. Les forces de cisaillement contribuent au dysfonctionnement endothélial chez les hypertendus mais pas chez les diabétiques de type 2. 16ème Journées d'HTA, Paris, 12-13 décembre 1996. Arch Mal Coeur Vaiss 1996;suppl:18 (O47)

Chapet O, Herbeth B, Sass C, Visvikis S, Siest G, Zannad F. Variations de l'épaisseur intima média en fonction de l'âge et du sexe dans un échantillon de sujets normotendus (la cohorte Stanislas). 16ème Journées d'HTA, Paris, 12-13 décembre 1996. Arch Mal Coeur Vaiss 1996;suppl:43 (P44)

Chapet O, Sass C, Herbeth B, Guéguen R, Visvikis S, Siest G, Zannad F. Interactions environnement-génétique dans le déterminisme de l'épaisseur intima média artérielle. Enseignements d'une étude de ségrégation familiale au sein de la cohorte Stanislas. 16ème Journées d'HTA, Paris, 12-13 décembre 1996. Arch Mal Coeur Vaiss 1996;suppl:20 (O54)

Sass C, Chapet O, Herbeth B, Siest G, Zannad F, Visvikis S. Polymorphisme I/D de l'enzyme de conversion de l'angiotensine I et épaisseur de la paroi artérielle : étude au sein de la cohorte Stanislas. 16ème Journées d'HTA, Paris, 12-13 décembre 1996. Arch Mal Coeur Vaiss 1996;suppl:14

(O31)

Sass C, Herbeth B, Zannad F, Siest G, Visvikis S. Pression artérielle et polymorphisme de l'apolipoprotéine E : étude au sein de la cohorte Stanislas. 16ème Journées d'HTA, Paris, 12-13 décembre 1996. Arch Mal Coeur Vaiss 1996;suppl:20 (O55)

Quilliot D, Fluckiger L, Ziegler O, Zannad F, Drouin P. Diminution de la variabilité de la fréquence cardiaque et de la pression artérielle au cours de l'obésité. 16ème Journées d'HTA, Paris, 12-13 décembre 1996. Arch Mal Coeur Vaiss 1996;suppl:24 (O69)

Fluckiger L, Boivin JM, Krafft R, Zannad F. Variabilité à court terme de la pression artérielle chez les transplantés cardiaques hypertendus. 16ème Journées d'HTA, Paris, 12-13 décembre 1996. Arch Mal Coeur Vaiss 1996;suppl:41 (P35)

1997

Guerci B, Boullier A, Meyer L, Delbachian I, Duriez P, Fruchart JC, Drouin P. Intraperitoneal insulin infusion does not influence LDL susceptibility to oxidation in well-controlled IDDM patients. 15th Workshop of the AIDSPIT Study Group, Innsbrück, Autriche, 26-28 Janvier 1997. Hormone and metabolic Research 1997;29:A3(06)

Quilliot D, Walters E, Duriez P, Fruchart JC, Drouin P, Ziegler O. Anomalies de composition des LDL au cours du diabète secondaire à la pancréatite chronique. ALFEDIAM, Amiens, 19-23 mars 1997. Diabète Métab 1997;23 (suppl.1):58 (abstract)

Quilliot D, Walters E, Duriez P, Fruchart JC, Drouin P, Ziegler O. Concentration et apoprotéine A-IV plasmatique au cours du diabète primitive et secondaire à la pancréatite chronique. ALFEDIAM, Amiens, 19-23 mars 1997. Diabète Métab 1997;23 (suppl.1):58 (abstract)

Khder Y, Quilliot D, Petermann R, Stoltz JF, Zannad F, Drouin P. Forces de cisaillement et dysfonctionnement endothélial chez les patients hypertendus et chez chez les patients diabétiques de type II. ALFEDIAM, Amiens, 19-23 mars 1997. Diabète Métab 1997;23 (suppl.1):51 (abstract)

Quilliot D, Walters E, Duriez P, Fruchart JC, Nabet F, Drouin P, Ziegler O. Statut en antioxydants dans la pancréatite chronique : effets du diabète. ALFEDIAM, Amiens, 19-23 mars 1997. Diabète Métab 1997;23 (suppl.1):59 (abstract)

Guerci B, Boullier A, Meyer L, Duriez P, Fruchart JC, Drouin P. Susceptibilité à l'oxydation des particules LDL au cours du DID traité par insulinothérapie intra-péritonéale. ALFEDIAM, Amiens, 19-23 mars 1997. Diabète Métab 1997;23 (suppl.1):44 (abstract)

Fluckiger L, Boivin JM, Krafft R, Zannad F. Short-term blood pressure variability in hypertensive cardiac transplant patients. 8th European Meeting on Hypertension, Milan, June 13-16, 1997 (poster). J Hypertens 1997;15(4):S16

Sass C, Chapet O, Herbeth B, Siest G, Visvikis S, Zannad F. I/D polymorphism of the angiotensin I converting enzyme and intima-media thickness in normotensive subjects from the Stanislas cohort. 8th European Meeting on Hypertension, Milan, June 13-16, 1997 (poster). J Hypertens 1997;15(4):S101

Sass C, Herbeth B, Zannad F, Siest G, Visvikis S. Blood pressure and apolipoprotein E genotypes in the Stanislas family study. 8th European Meeting on Hypertension, Milan, June 13-16, 1997 (poster). J Hypertens 1997;15(4):S192

Zannad F for the General Physicians Investigators Group. Time-effect profile of once daily amlodipine vs perindopril evaluated by ambolatory blood pressure monitoring. 8th European Meeting on Hypertension, Milan, June 13-16, 1997 (poster). J Hypertens 1997;15(4):S210

Zannad F, Chapet O, Sass C, Herbeth B. Environmental and genetic interactions in determining the intima-media thickness. Findings from a study of familial segregation from the Stanislas Group. 8th European Meeting on Hypertension, Milan, June 13-16, 1997 (poster). J Hypertens 1997;15(4):S210

Zannad F, Chapet O, Herbeth B, Sass C, Visvikis S, Siest G. Age and gender related changes in intima media thickness of carotid and femoral arteries in normotensive subjects (the Stanislas cohort). 8th European Meeting on Hypertension, Milan, June 13-16, 1997 (poster). J Hypertens 1997;15(4):S57

Khder Y, Petermann R, Drouin P, Zannad F. Shear stress abnormalities contribute to endothelial dysfunction in hypertension but not in type II diabetes. 8th European Meeting on Hypertension, Milan, June 13-16, 1997 (poster). J Hypertens 1997;15(4):S68

Quilliot D, Fluckiger L, Drouin P, Ziegler O, Zannad F. Obesity and insulin resistance alters the autonomic nervous system control of heart rate and blood pressure. 8th European Meeting on Hypertension, Milan, June 13-16, 1997 (poster). J Hypertens 1997;15(4):S186

Quilliot D, Walters E, Duriez P, Fruchart JC, Drouin P, Ziegler O. Apolipoprotein A-IV in pancreatic diabetes anbd in type I diabetes mellitus. Meeting of the American Diabetes Association, Boston, Juin 1997 (poster). Diabetes 1997;46:220A(0624)

Quilliot D, Fluckiger L, Drouin P, Ziegler O, Zannad F. Obesity and insulin resistance alters the autonomic nervous system control of heart rate and blood pressure. Meeting of the American Diabetes Association, Boston, Juin 1997 (poster). Diabetes 1997;46:161A(0624)

Guerci B, Meyer L, Boullier A, Duriez P, Fruchart JC, Drouin P. Intraperitoneal insulin infusion does not influence LDL susceptibility to oxidation in well-controled IDDM patient. Meeting of the American Diabetes Association, Boston, Juin 1997 (poster). Diabetes 1997;46:220A(0843)

Guerci B, Vergès B, Paul JL, Dousset B, Durlach V. Relationship between insulin resistance, leptin and postprandial lipemia responses in normal and overweight patients. Meeting of the American Diabetes Association, Boston, Juin 1997 (communication orale). Diabetes 1997;46:60A(0234)

Juillière Y, Preiss JP, Alla F, Briancon S, Mertès PM, Villemot JP, Aliot E, Zannad F on behalf of the EPICAL Investigators. Comparison between ischaemic cardiomyopathy and dialted cardiomyopathy from a large French epidemiological study on severe congestive heart failure (EPICAL). XIXth Congress of the European Society of Cardiology, Stockholm, 22-28 Août 1997. Eur H J 1997;18:407 (P2294)

Sass, B. Herbeth, F. Zannad, R. Guéguen, G. Siest, S. Visvikis. Familial study of genetic determinants of carotid intima-media thickness in an healthy populaiton. Implication of apolipoprotein E polymorphism. XIth International Symposium on Atherosclerosis, Paris, 5-9 Octobre 1997. Atherosclerosis 1997;134:379

Zannad F, Briançon S, Juillière Y, Mertès PM, Alla F, Virion JM, Villemot JP, Aliot E. Epidemiology of severe congestive heart failure in the post-ACE inhibitors. The prospective community based EPICAL program. 70th Scientific Session, American Heart Association, Orlando 8-13 Novembre 1997.

Juillière Y, Alla F, Preiss JP, Briançon S, Mertès PM, Villemot JP, Aliot E, Zannad F. Influence of systemic hypertension or excessive alcohol consumption on one-year mortality in nonischemic dilated cardiomyopathy. 70th Scientific Session, American Heart Association, Orlando 8-13 Novembre 1997. Circulation 1997;96 (suppl):I-696 abstract n°3899 (poster)

Zannad F, Chati C, Guest M. Long-term comparison of fosinopril with enalapril in patients with mild to moderate chronic heart failure. 70th Scientific Session, American Heart Association, Orlando 8-13 Novembre 1997. Circulation 1997;96 (suppl):I-612 abstract n°3417 (poster)

Guerci B, Paul JL, Verges B, Durlach V. Etude de la lipémie postprandiale chez des sujets normolipémiques présentant une surcharge pondérale modérée. Journées francophones de nutrition. 26-28 Novembre 1997, Paris. Nutr Clin metabol 1997;11 (suppl):318.

Zannad pour le groupe de médecins généralistes investigateurs. Profil temps-activité de l'amlodipine et du périndopril en monoprise quotidienne évalué par mesure ambulatoire de la pression artérielle. 17èmes Journées d'Hypertension Artérielle, Paris, 11-12 décembre 1997. Arch Mal Coeur Vaiss 1997;90:16 (O37)

Juillière Y, Virion JM, Alla F, Preiss JP, Briançon S, Mertès PM, Villemot JP, Zannad F et les investigateurs EPICAL. Influence de l'hypertension artérielle et de la consommation excessive d'alcool sur la mortalité à un an dans la cardiomyopathie dilatée non-ischémique. 17èmes Journées d'Hypertension Artérielle, Paris, 11-12 décembre 1997. Arch Mal Coeur Vaiss 1997;90:52 (P72)

Legras B, Zannad F, Challier B. Intérêt de la modélisation de la pression artérielle par analyse de Fourier pour la détermination de la cinétique nocturne. 17èmes Journées d'Hypertension Artérielle, Paris, 11-12 décembre 1997. Arch Mal Coeur Vaiss 1997;90:53 (P75)

Magnin-Poull I, Adam M, De Chillou C, Sadoul N, Zannad F, Aliot E. Time course of heart rate variability measured by 24-hour. Pace 1997;20(5):1505

1998

Salvio C, Zannad F. The combination of 2 antihypertensive agents potentiate the magnitude and the duration of action of effects on blood pressure. Congrès de la Société Française de Pharmacologie, Nancy, 23-25 mars 1998. Fund Clin Pharmacol 1998, 12:361

Zannad F, Bernaud C. Ambulatory blood pressure monitoring for the evaluation of the time-effect profile of amlodipine vs perindopril. Congrès de la Société Française de Pharmacologie, Nancy, 23-25 mars 1998. Fund Clin Pharmacol 1998, 12:372

Zannad F, Fluckiger L. More effective blood pressure control with felodipine - metoprolol combination than with amlodipine. 24-hour ambulatory blood pressure monitoring. Congrès de la Société Française de Pharmacologie, Nancy, 23-25 mars 1998. Fund Clin Pharmacol 1998,12:373

Zannad F, Fluckiger L. Ambulatory blood pressure monitoring for the evaluation of the time-effect profile of trandolapril versus quinapril. Congrès de la Société Française de Pharmacologie, Nancy, 23-25 mars 1998. Fund Clin Pharmacol 1998,12:372

Salvio C, Zannad F. Trough/peak ratios of once daily beta-blockers and diuretics comply with FDA recommendations. Congrès de la Société Française de Pharmacologie, Nancy, 23-25 mars 1998. Fund Clin Pharmacol 1998,12:362

Khder Y, Zannad F. Calcium antagonists and thiazide diuretics have opposite effects on blood rheology and radial artery compliance in arterial hypertension. A randomized double-blind study. Congrès de la Société Française de Pharmacologie, Nancy, 23-25 mars 1998. Fund Clin Pharmacol 1998, 12:337

Echemann E, Virion JM, Briançon S, Juillière Y, Mertès P-M, Zannad F. Determinants of ambulatory prescriptions of ACE inhibitors in heart failure: the EPICAL study. Congrès de la Société Française de Pharmacologie, Nancy, 23-25 mars 1998. Fund Clin Pharmacol 1998, 12:327

Guerci B, Paul JL, Vergès B, Durlach V, Drouin P. Anomalies de l'épuration postprandiale des lipoprotéines riches en triglycérides chez des patients insulinorésistants normolipidiques avec surcharge pondérale. Congrès ALFEDIAM 24-27 mars 1998. Diabète Métabol 1998;24:LI

Hadjadj S, Paul JL, Durlach V, Verges B, Drouin P, Guerci B. Métabolisme postprandial des lipoprotéines et de la vitamine A. Modifications circadiennes. Congrès ALFEDIAM 24-27 mars 1998. Diabète Métabol 1998;24:LII

Zannad F, Bernaud C for the General Physicians Investigators group. Ambulatory blood pressure monitoring for the evaluation of the time-effect profile of amlodipine vs perindopril. 30th scientific meeting of the ASH, New York, May 13-16, 1998; Am J Hypertens 1998;11: D 053

Virion JM, Zannad F. Influence of systemic hypertension on one-year mortality in severe congestive heart failure. 30th scientific meeting of the ASH, New York, May 13-16, 1998; Am J Hypertens 1998;11: P 044

Zannad F for the French Multicentre Group. More effective blood pressure control with felodipine metoprolol combination than with amlodipine: 24-hour ambulatory blood pressure monitoring. 30th scientific meeting of the ASH, New York, May 13-16, 1998; Am J Hypertens 1998;11: E 110

Kessler M, Echemann M, Zannad F and the Association des Néphrologues de l'Est. Determinants of left ventricular hypertrophy in chronic hemodialysis patients âged more than 50 years. XXXV congress of the European Renal Association. Rimini 6-9 juin 1998. Hemodialysis 1998;suppl. : 286

Guerci B, Meyer L, Boullier A, Duriez P, Fruchart JC, Drouin P. Intraperitoneal insulin infusion does not influence cholesterol efflux in well-controlled IDDM patients. 58th Annual Scientific Meeting of the ADA, Chicago 13-16 juin 1998. Diabetes, 1998;47:A101

Echemann M, Briancon S, Juillière Y, Virion JM, Mertès PM, Zannad F. Determinants of ambulatory prescriptions of angiotensin converting enzyme inhibitors in heart failure : the EPICAL study. Xxth congress of the European Society of Cardiology, Vienne, 22-26 Août 1998 (poster). Eur H J 1998, 1998;19 (suppl):302

Alla F, Juillière Y, Virion JM, Briançon S, Mertes PM, Villemot JP, Zannad F and the Epical Investigators. Influence of cardiac thythm on one-year mortality in severe congestive heart failure due to ischemic or noninschemic dilated cardiomyopathy. XXth Congress of the European Society of Cardiology, 22-26 Août 1998, Vienne, Autriche, Eur H J 1998;19 (suppl):511

Echemann M, Briançon S, Juillière Y, Virion JM, Mertès PM, Zannad F. Déterminants de la prescription ambulatoire des inhibiteurs de l'enzyme de conversion dans l'insuffisance cardiaque sévères : l'étude EPICAL. Congrès Conjoint ADELF-IEA, Bordeaux, 14-17 septembre 1998. Revue d'Epidémiologie et de Santé Publique 1998;46 (suppl 1):S66

Alla F, Briançon S, Juillière Y, Mertès PM, Villemot JP, Zannad F et les investigateurs EPICAL. La qualité de vie est-elle un facteur pronostique indépendant dans l'insuffisance cardiaque ? Congrès Conjoint ADELF-IEA, Bordeaux, 14-17 septembre 1998. Revue d'Epidémiologie et de Santé Publique 1998;46 (suppl 1):S64

Quilliot D, Fluckiger L, Zannad F, Drouin P, Ziegler O, Zannad F. Impaired autonomic cardiovascular regulation in obesity : influence of age and body mass index. 71st Scientific Sessions of the American Heart Association. Dallas 8-11 Novembre 1998. Circulation 1998;98(17):I-866 (4543)

Zeghari N, Vidal H, Percher S, Meyer L, Ziegler O, Guerci B, Donner M, Drouin P. Adipose PPAR mRNA expresion in insulin resistant obese patients : relationship with adipocyte membrane phospholipids. Int J Obesity 1998;22:S100(P20)

1999

Lefrandt JD, Urbigkeit A, Sevre K, Castellano M, Hausber M, Fallon M, Fluckiger L, Heitmann J, Rostrup M, Agabiti Rosei E, Rahn KH, Murphy M, Zannad F, de Kam PJ, Smit AJ. Autonomic balance is shifted toward increased vagal predominance during verapamil compared with amlodipine in patients with mild to moderate hypertension : The VAMPHYRE study.J Hypertens 1999;17(suppl 3):S133-S134

Lefrandt JD, Urbigkeit A, Sevre K, Castellano M, Hausber M, Fallon M, Fluckiger L, Heitmann J, Rostrup M, Agabiti Rosei E, Rahn KH, Murphy M, Zannad F, de Kam PJ, Van Roon AM, Smit AJ. Divergent Effects of Dihydropyridine and Phenylalkylamine Calcium Antagonist on Plasma Norepinephrine before and after Cold Pressor Test in Mild to Moderate Hypertension J Hypertens 1999;17(suppl 3):S132

Lefrandt JD, Urbigkeit A, Sevre K, Castellano M, Hausber M, Fallon M, Fluckiger L, Heitmann J, Rostrup M, Agabiti Rosei E, Rahn KH, Murphy M, Zannad F, de Kam PJ, Van Roon AM, Smit AJ. Improved Short-Term Blood Pressure Control by Treatment with Calcium Antagonists in Patients with Mild to Moderate Hypertension. J Hypertens 1999;17(suppl 3):S66

Echemann M, Zannad F, Briançon S, Alla F, Virion JM, Juillière Y, Villemot JP. Antithrombotic therapy is associated with better survival in patients with severe heart failure. Eur Heart J 1999;20:28

Guerci B, Meyer L, Salle A, Charrié A, Dousset B, Ziegler O, Drouin P. Comparaison de la détérioration métabolique durant 5 heures d'interruption du traitement par pompe portable à insuline chez des diabétiques de type 1 traités par analogue Lispro ou Vélosuline. Diabetes metab 1999(supp1);25:34

Guerci B, Delbachian I, Lehert P, Lebealle B, Droiuin P, Meyer L. La metformine diminue les besoins en insuline au cours du diabète de type I : résultats d'une étude prospective chez 62 patients traités par pompe externe. Diabetes metab 1999(supp1);25:58

Berrichi H, Tiberge M, Zannad F. Behavioral activities as a predictive parameters in the detection of subtle variations of vigilance in real-life driving situations. Conference: Diagnosis and treatment of sleep breathing disorders, Grenoble, 9-11 Décembre 1998. Sleep Research, 1999; suppl:54 (abstract 43)

Teculescu D, Montaut-Vérient B, Virion JM, Cornette A, Hannhart B. Snoring in an active male population from North Eastern France. Am J Respir Crit Care Med 1999;159 (suppl3):A564

Meyer L, Delbachian I, Lehert P, Cugnardey N, Drouin P, Guerci B. Continuous subcutaneous insulin infusion in type I diabetes : insulin-sparing effect of metformin. Diabetologia, 1999;42:A226

Quilliot D, Fluckiger L, Hammadi M, Virion JM, Drouin P, Ziegler O, Zannad F. Diminution de la variabilité de la fréquence cardiaque du sujet obèse : rôle de l'âge et de la composition corporelle. XIXes Journées de l'hypertension Artérielle, Paris, 9-10 décembre 1999. Arch Mal Coeur Vaiss 1999;92:46(P87)

Kearney-Schwartz A, Virion JM, Fluckier L, Khder Y, Stoltz JF, Drouin P, Zannad F. La géométrie, la compliance et la distensibilité de l'artère radiale chez les patients hypertendus diabétiques type 2. XIXes Journées de l'hypertension Artérielle, Paris, 9-10 décembre 1999. Arch Mal Coeur Vaiss 1999;92:31(P2)

Kearney-Schwartz A, Virion JM, Fluckiger L, Khder Y, Stoltz JF, Drouin P, Zannad F. Hyperstimulation endothéliale par augmentation des contraintes de cisaillement parietales chez les patients hypertendus diabétiques. XIXes Journées de l'hypertension Artérielle, Paris, 9-10 décembre 1999. Arch Mal Coeur Vaiss 1999;92:31(P3)

Zannad F, Ziegler O, Gille B, Grentzinger A, Bruntz JF, Hammadi M, Fluckiger L, Boivin JM, Hanotin C. Un traitement amaigrissant par Sibutramine n'entraîne pas de modification cliniquement significative des paramètres cardiovasculaires, de la géométrie et de la fonction du ventricule gauche et des valves cardiaques. XIXes Journées de l'hypertension Artérielle, Paris, 9-10 décembre 1999. Arch Mal Coeur Vaiss 1999;92:41(P57)

Pitt B, Zannad F, Remme WJ, Cody RJ. Spironolactone appears beneficial regardless of ejection fraction : the RALES trial. Circulation 1999;100:I-298

Lefrandt JD, Heitman J, Sevre K, Castellano M, Hausberg M, Murphy M, Zannad F, et al. Sex differences in autonomic function in paients with mild to moderate hypertension. Circulation 1999;100:I-608

Berrichi H, Zannad F, Hannhart B, Tiberge M. Drowsiness driver: a reliable neurophysiological parameter. Sleep 1999;22:S168-9

Teculescu D, Mayeux L, Montaut B, Hannhart B, Virion JM. Sleep disordered breathing in a sample of French males : can job represent a risk factor ? Eur Respir J 1999;14:492S

Teculescu D, Mayeux L, Montaut-Verien B, Cornette A, Michaely JP, Hannhart B, Virion JM. Prévalence des arrêts respiratoires pendant le sommeil dans une population masculine en activité. 1999

Zeghari N, Vidal H, Perche S, Meyer L, Ziegler O, Guerci V, Donner M, Drouin P. Adipose peroxisome proliferator-activated receptor mRNA expression in insulin-resistant obese patients relationship with adipocyte membrane phospholipids. Lipids 1999;34:S161

2000

Pallaud C, Sass C, Zannad F, Siest G, Visvikis S. Apo CIII, CETP, Fibrinogen, MTHFR and PON are genetic determinants of carotid protid intima media thickness in the Stanislas cohort. Arch Mal Cœur Vaiss 2000;93:129

Gosse P, Sheridan D, Zannad F, Dubourg O, Guéret P, Karpov Y, de Leeuw P, Palma-Gamiz JL, Pessina A, Motz W, Degaute JP, Chastang C. Régression de l'hypertrophie ventriculaire gauche chez l'hypertendu traité par indapamide 1,5 mg ou énalapril 20 mg : l'étude LIVE. Arch Mal Cœur Vaiss 2000;93:16

Zannad F, Alla F, Dousset B, Pitt B On Behalf Of The Rales Steering Committee And Investigators. Survival benefits of spironolactone therapy may be explained by the limitation of the excessive extracellular matrix turnover in patients with CHF: insights from the RALES trial. JACC 2000;35 (suppl A):203A

Alla F, Briançon S, Juilliere Y, Mertes PM, Villemot JP, Guillemin F, Zannad F. Quality of life measures predict mortality and hospitalization in patiens with advanced heart failure. Insights from the EPICAL study. JACC 2000;35(suppl A):238A

Guerci B, Paul JL, Verges B, Drouin P, Durlach V. Standardisation et validation en 3 points de l'analyse de l'épuration lipidique postprandiale : étude sur une population de témoins, obèses et diabétiques de type II. ALFEDIAM, Grenoble, 21-25 mars 2000. Diabetes et metab 2000;26:44

Guerci B, Mattei P, Younsi M, Paul JL, Ziegler O, Donner M, Drouin P. Anomalies postrprandiales de composition phospholipidique des HDL chez l'obèse insulinorésistant. ALFEDIAM, Grenoble, 21-25 mars 2000. Diabetes et metab 2000;26:43

Zannad F, Ziegler O, Gilles B, Grentzinger A, Bruntz JF, Hammadi M, Fluckiger L, Boivin C, Drouin P and the GPs investigators. Antiobesity therapy wih sibutramine has no clinically significant effect on cardiovascular variables, ventricular dimensions and heart valves in obese patients. Am J Hypertens 2000;13:86A

Kearney-Schwartz A, Virion JM, Khder Y, Drouin P, Zannad F. Geometry, compliance and distensibility of the radial artery in hypertensive patients with type 2 diabetes. Am J Hypertens 2000;13:193A

Kearney-Schwartz A, Virion JM, Khder Y, Stoltz JF, Drouin P, Zannad F. Endothelial hyperstimulation with increased wall shear stress in hypertensive diabetic type 2 patients. Am J Hypertens 2000;13:194A

Hannhart B, Teculescu D, Medina JJ, Marchand M, Peslin R, Polu JM. Airway obstruction detected continuously by forced oscillation technique during sleep apnea in obese patients did not appear to be only an inspiratory related event. Am J Crit Care Med 2000;161:A352

Hannhart B, Teculescu D, Medina JJ, Marchand M, Peslin R, Polu JM. Airway occlusion, monitored during sleep by forced oscillation technique, is not systematically dependent on the inspiratory effort in obese patient. Eur Respir J 2000;15(suppl 31):166S

Teculescu D, Hannhart B, Michaely JP, Virion JM, Bohadana AB. Daytime sleepiness : prevalence and associations in a sample of French males. Eur Respir J 2000;15(suppl 31):450S, A

Kearney-Schwartz A, Virion JM, Khder Y, Drouin P, Zannad F. Geometry, compliance and distensibility of the radial artery in hypertensive patients with type 2 diabetes. J Hypertens 2000;18 (suppl 4):S 189

Kearney-Schwartz A, Virion JM, Khder Y, Stoltz JF, Drouin P, Zannad F. Endothelial hyperstimulation with increased wall shear stress in hypertensive diabetic type 2 patients. J Hypertens 2000;18 (suppl 4):S 191

Zannad F, Alla F, Echemann M, Fagniani F, Virion JM, Juillière Y, Briançon S. Decreased renal function is a major determinant of outcome, health management and ACE inhibitor therapy prescription and dosage in patients with congestive heart failure. Results from the EPICAL study. Eur Heart J 2000;21:537

Zannad F, Fagnani F, Buteau L, Virion JM, Alla F, Echemann M, Juillière Y, Briancon S. Factors contributing to health care resource use and to cost related to the management of patients with congrestive heart failure : results from the EPICAL study. Eur Heart J 2000;21:229

Sass C, Zannad F, Pallaud C, Visvikis S. Apo CIII, CETP, Fibrinogen and MTHFR and genetic determinants of carotid intima media thickness in healthy men (the STANISLAS Cohort). >I>Eur Heart J 2000;21:611

Zannad F, Alla F, Dousset B, Perez A, Pitt B on behalf of the RALES Steering Committee and Investigators. Mechanisms contributing to the survival benefit with aldosterone antagonist therapy in heart failure : Effects on neurohormones and cardiac fibrosis. Substudy of RALES. Eur Heart J 2000;21:22

Zannad F, Alla F, Dousset B, Pitt B. Limitation of the excessive extracellular matrix turnover is a major determinant of the beneficial effect of spironolactone on survival inpatients with CHF: Insights from the RALES trial. Eur J Heart Failure 2000;2:98

Zannad F, Alla F, Dousset B. Determinants and prognostic value of serum markers of cardiac fibrosis in heart failure: results from the RALES database. Eur J Heart Failure 2000;2:104

Teculescu D, Mayeux L, Montaut Verient B, Virion JM, Michaely JP, Hannhart B. Troubles ventilatoires du sommeil selon le profil socioprofessionnel chez des employés du tertiaire. Rev Epidémiol Santé Publ 2000;48(supp 3) :S149

Lefrandt JD, Heitmann J, Sevre K, Castellano M, Hausberg M, Fallon M, Fluckiger L, Urbigkeit A, Rostrup M, Agabiti Rosei E, Rahn KH, Murphy M, Zannad F, De Kam PJ, Smit AJ. Contrasting effects of verapamil and amlodipine on cardiovasculair stress responses in hypertension. J Hypertens 2000;18 (suppl 2):S98

Guerci B, Younsi M, Paul JL, Ziegler O, Donner M, Drouin P. Relation entre le degré d'insulino résistance et l'enrichissement postprandial en phospholipides des HDL de patients obèses androïdes. Annales d'Endocrinologie 2000;61:392

Lefrandt JD, Heitmann J, Sevre K, Castellano M, Hausberg M, Fallon M, Fluckiger L, Urbigkeit A, Rostrup M, Agabiti Rosei E, Rahn KH, Murphy M, Zannad F, De Kam PJ, Smit AJ. Effects of verapamil and amlodipine on plasma norepinephrine and cardiovasculair load during stress in hypertension. J Hypertens 2000;18 (suppl 4):S157

Sass C, Pallaud C, Zannad F, Visvikis S. Association entre le polymorphisme LEU554PHE de la E-selectine et la pression artérielle au sein de la cohorte Stanislas. Arch Mal Cœur Vaiss 2000;93:17

Pallaud C, Sass C, Zannad F, Siest G, Visvikis S. L'apo CIII, la CETP, le fibrinogène et la MTHFR sont des déterminant génétiques de l'épaisseur intima media de la carotide chez des hommes sains (la cohorte Stanislas). Arch Mal Cœur Vaiss 2000;93:17

Zannad F, Alla F, Dousset B, Kearney-Schwartz A. Sensitivity, specificity and prognostic value of serum markers of cardiac extra-cellular matrix turn-over in heart failure. J Am Coll Cardiol 2001, 37:166A

Quilliot D, Pizzi D, Radauceanu A, Hannhart B, Cornette A, Drouin P, Ziegler O. Evaluation de la prévalence du syndrome d'apnées du sommeil dans une population d'obèses morbides à l'aide d'un enregistrement polygraphique nocturne (merlin). Nutr Clin Métabol 2000;14:147-69

Zannad F, Grentzinger A, Bruntz JF, Boivin JM, Hanotin C, Igau B, Drouin P. Sibutramine's effects on ventricular dimensions and heart valves in obese patients during weight reduction.

Iaria P, Hanon O, Radauceanu A, Ducloux D, Begasse F, Achard JM, Denolle R, Girerd X au nom du Club des Jeunes Hypertensiologues. Les hypertendus légers sont-ils vraiment des patients asymptomatiques? Arch Mal Cœur Vaiss 2000

Hanon O, Mourad JJ, Mounier-Vehier C, Marquand A, Fauvel JP, Radauceanu A, Girerd X au nom du Club des Jeunes Hypertensiologues. La possession d'un appareil d'automesure tensionnelle contribue à améliorer l'éducation des patients hypertendus. Arch Mal Cœur Vaiss 2000

2001

Girerd X, Fourcade J, Brillet G, Silhol F, Braunstein C, Kearney-Schwartz A, Radauceanu A, Achard JM, Hanon O on behalf of the Club des Jeunes Hypertensiologues. The compliance evaluation test: a validated tool for detection of nonadherence among hypertensive treated patients. J Hypertens 2001,19(2):S74

Zannad F. Aldosterone antagonists in the treatment of heart failure: the RALES study. Arch Mal Cœur Vaiss 2001;94 (suppl.):36

Zannad F. Recent clinical trials in pharmacological treatment of heart failure. Cardiovasc Drug Therapy 2001;15:117

Zannad F. Cardiac extracellular matrix as a target for pharmacotherapy in congestive heat failure. Cardiovasc Drug Therapy 2001;15:12

Böhme Ph, Kearney Schwartz P, Paul JL, Zannad F, Ziegler O, Drouin P, Guerci B. Dysfonction endothéliale du sujet coronarien : influence des lipides postprandiaux. Diabetes & metabolism 2001;27 (suppl 1) : S65

Sass C, Pallaud C, Zannad F, Visvikis S. Association entre le polymorphisme Leu554phe de la E-selectine et la prssion artérielle (cohorte Stanislas). Arch Mal Cœur Vaiss 2001;94:390

Zannad F, Alla F, Virion JM, Briancon S, Juillière Y. Long term, 5 year-survival and prognostic factors in patients hospitalized with advanced heart failure, in the EPICAL study. Eur Heart J, 2001;22:259

Zannad F, Alla F, Dousset B, Kearney Schwartz A, Lefevre N. Changes of serum markers of cardiac extracellular matrix turnover in heart failure and high risk patients. Eur Heart J, 2001;22:378

Radauceanu A, Virion JM, Fluckiger L, Zannad F. Time effect profile of antihypertensive agents assessed with trough/peak ratio: an ambulatory blood pressure monitoring study with trandolapril vs quinapril. Fund Clin Pharmacol 2001,15 (suppl 1):92

Zannad F, Ziegler O, Gilles B, Grentzinger A, Bruntz, JF, Hammadi M, Boivin JM, Hanotin C, Drouin P. Reduction in left ventricular mass with weight loss on sibutramine treatment for obesity. Fund Clin Pharmacol 2001,15 (suppl 1):123

Böhme P, Kearney Schwartz A, Paul JL, Zannad F, Ziegler O, Drouin P. Postprandial lipid metabolism and endothelial dysfunction in men with coronary heart disease. Diabetes 2001;50 (suppl 2):A450

Alla F, Quilliot D, Dousset B, Ziegler O, Böhme P, Zannad F. L'insulino-résistance est un facteur indépendant de fibrose cardiaque chez l'obèse. Arch Mal Cœur Vaiss 2001;95:6

Kearney Schwartz A, Bernaud C, Stoltz JF, Drouin P, Zannad F. Modifications hémorhéologiques, diamètre et compliance artériels chez des patients hyperrtendus diabétiques de type 2 : influence du traitement antihypertenseur. Arch Mal Cœur Vaiss 2001;95:20

Zannad F. Epidémiologie de l'insuffisance cardiaque avancée en Lorraine. Arch Mal Cœur Vaiss 2001;94 (suppl.):83

Zannad F. Le traitement pharmacologique de l'insuffisance cardiaque chronique (ICC). La situation en France. Arch Mal Cœur Vaiss 2001;94 (suppl.):113

Devaux Y, Seguin C, Grosjean S, De Talance N, Meistelman C, Zannad F, Mertes PM, Longrois D. Inducible NO synthase (NOS2) – Cyclooxygenases (COX) cross-talk in vivo : implication for pharmacological inhibition of NOS2 activity. Arch Mal Cœur Vaiss 2001;94:354

Mercenier C, Hassan N, Olivier P, Marie PY, Laurens MH, Grentzinger A, Zannad F, Danchin N, Karcher G, Bertrand A. Failure to prevent exercise-spet ischemia, in coronary artery disease treated medically by beta-blockers, leads to a delayed but dramatic worsening of outcome. Eur J Nuclear Med 2001;28:977

Ziegler O, Delbachian I, Poissonet CM, Vidailllhet M, Strosberg AD, Mejean L. Effets synergiques de 4 polymorphismes génétiques fréquents sur la masse grasse. L’étude GENOLOR I. Programme scientifique et Communications. Congrès commun AFERO, AFN & SNDLF – “Nutrition – Obésité 2001” 29-30 novembre 2001

Ziegler O, Delbachian I, Poissonet CM, Vidailllhet M, Strosberg AD, Mejean L. Synergic effect of 4 common gene polymorphisms on obesity risk. The GENOLOR I study. Int J Obesity 2001, 25, suppl 2, S5-S6

Ogier V, Ziegler O, Mejean L, Stricker-Kongrad A. Relationship between circulating soluble leptin receptor, leptin and fat mass in humans. Int J Obesity 2001,25, suppl 2, S25-S26

Younsi M, Delbachian E, Quillot D, Al-Makdissy, Drouin P, Donner M, Ziegler O. Relations entre les phospholipides de la membrane érythrocytaire et l’insulinémie chez des femmes obèses non diabétiques: effets de la perte de poids. Programme scientifique et Communications. Congrès commun AFERO, AFN & SNDLF – “Nutrition – Obésité 2001” 29-30 novembre 2001

Ogier V, Delbachian I, Mejean L, Ziegler O. Intérêt de la mesure de la leptinémie plasmatique dans l’étude épidémiologique Génolor. Programme scientifique et Communications. Congrès commun AFERO, AFN & SNDLF – “Nutrition – Obésité 2001” 29-30 novembre 2001

Bohme P, Kearney-Schwartz A, Ziegler O, Paul JL, Zannad F, Drouin P, Guerci B. Dysfonction endothéliale et métabolisme lipidique postprandial chez le sujet coronarien: influence des acides gras libres. Programme scientifique et Communications. Congrès commun AFERO, AFN & SNDLF – “Nutrition – Obésité 2001” 29-30 novembre 2001

Guerci B, Bohme Ph, Franck P, Floriot M, Durain D, Drouin P. Supériorité de la mesure de cétonémie par prélèvement capillaire comparativement à la mesure de cétonurie: application à la cétose du patient diabétique de type 1 traité par pompe portable. Diabetes Métab 2000, 28; P112.

2002

Alla F, Quillot D, Ziegler O, Bohme Ph, Zannad F. Insulin-resistance is an independent determinant of cardiac fibrosis in obesity. Journal of Hypertension, June 2002, 20 (suppl 4), S59

Kearney-Schwartz A, Bernaud C, Stoltz JF, Drouin P, Zannad F. Influence of antihypertensive therapy on hemorheological modifications, arterial diameter and compliance in hypertensive type 2 diabetic patients. Journal of Hypertension, June 2002, 20 (suppl 4), S72

Zannad F, Alla F, Dousset B, Kearney-Schwartz A, Lefevre N. Changes of serum markers of cardiac extra-cellular matrix turnover in heart failure and high risk patients. Journal of Hypertension, June 2002, 20 (suppl 4), S2

Zannad F, Alla F, Echemann M, Hacquard G, Risse B, Kessler M. Cardiovascular mortality in chronic haemodialysis patients: CORDIAL, a 3-year follow up cohort study. Eur Heart J 2002, 23:107

Zannad F, Cohen Solal A, Desnos M, Guize LJ, Juillière Y, Mebazza A, Rouge P, Samii K on behalf of the EFICA Investigators. Clinical and etiological features, management and outcomes of acute heart failure: the EFICA cohort study. Eur Heart J 2002, 23:579

Alla F, Briançon S, Zannad F. Elaboration and Validation of a Prognostic Classification for Severe Chronic Heart Failure: Data from EPICAL and RALES studies. JACC 2002, 39(5):802-1

Radauceanu A, Boivin JM, Bernaud C, Zannad F. Durée d’action et efficacité résiduelle après omission de dose de l’Amlodipine et du Valsartan dans une population d’hypertendus. Arch Mal Cœur Vaiss 2002, 95:P118

Boivin JM, Radauceanu A, Bernaud C, Zannad F. Effets comparés de l’Amlodipine et du Valsartan sur la pression artérielle résiduelle, chez des patients hypertendus suivis en ambulatoire. Arch Mal Cœur Vaiss 2002, 95:P119

Boivin JM. PAPYRUS: Programme d’Amélioration de la Prise en charge de l’hYpertension et des facteurs de Risque Usuels associés en Soins de ville. Arch Mal Cœur Vaiss 2002 (poster), 95:P44

Guerci B, Böhme Ph, Kearney-Schwartz A, Ziegler O, Paul JL, Zannad F, Drouin P. Lipides postprandiaux et dysfonction endothéliale du sujet coronarien rôle des acides gras libres. Annales d'Endocrinologie 2002, 63(4):283

Zannad F. Aldosterone antagonists for all heart failure patients? Arch Mal Cœur Vaiss 2002, 95(3):47

Juillière Y, Alla F, Zannad F, Briançon S. Epidémiologie de l’insuffisance cardiaque sévère. Arch Mal Cœur Vaiss 2002, 95(3):20

Alla F, Quilliot D, Dousset B, Ziegler O, Bohme Ph, Zannad F. Insulin-resistance is an independent determinant of cardiac fibrosis in obesity. Circulation, 2002,106(19):2119

Guerci B, Bohme Ph, Kearney-Schwartz A, Ziegler O, Paul JM, Zannad F, Drouin P. Lipides postprandiaux et dysfonction endothéliale du sujet coronarien: rôle des acides gras libres. Annales d'Endocrinologie 2002, 63(4):C035

Fournier N, Ziegler O, Paul JL, Goudouneche D, Drouin P, Guerci B. Etude de la capacité du sérum de femmes obèses androïdes à promouvoir l'efflux de cholestérol de cellules d'hépatome de rat fu5ah ou macrophagiques de souris J774 préretraitées par l'amp cyclique. Annales d'Endocrinologie 2002, 63(4):P161

2003

Pitt B, Remme W, Zannad F, Neaton J, Gatlin M, Roniker B, Hurley S, Bittman R. EPHESUS (Eplerenone Post AMI-Heart Failure Efficacy and Survival Study): a double-blind, randomized, placebo-controlled trial evaluating the safety and efficacy of eplerenone in patients with heart failure following acute myocardial infarction. JACC 2003

Boivin JM, Radauceanu A, Bernaud C, Zannad F, and the CIC General Practitioners Investigator’s Group. Comparison of antihypertensive trough effect of amlodipine versus valsartan in hypertensive outpatients. J Hypertens 2003, 21 (suppl 4): S271

Radauceanu A, Boivin JM, Bernaud C, Zannad F, and the CIC General Practitioners Investigator’s Group. Duration of action and BP lowering after dose omission of amlodipine and valsartan in hypertensive patients. J Hypertens 2003, 21 (suppl 4): S178

Strumph P, Charbonnel B, Miossec P, Porte F, Le Bealle B. EMS 257, a new oral antidiabetic, improves glycemic control in type 2 diabetic patients. American Diabetes Association - 63 Scientific Sessions, June 13-17, 2003 New Orleans, (poster)

Zannad F. Chronic heart failure and activation of sympathetic nervous system and RAAS : progression of detrimental steps. Eur J Heart Failure Juin 2003

Moulin F, Radauceanu A, Djaballah W, Dousset B, Alla F, Marie PY, Karcher G, Aliot E, Zannad F. Chronic myocardial ischemia is associated with changes in serum markers of cardiac extra-cellular matrix turnover contributing to cardiac fibrosis. Circulation 2003,108 (17) :3052

Remme W, Mc Murray J, Rauch B, Zannad F, Keukelaar K, Cohen-Solal A, Ruzyllo W, Lopez-Sendon J on behalf of the SHAPE study group. SHAPE (study of heart failure awareness and perception in Europe): a pan-European general public survey on awareness and perception of the clinical, social and economic importance of heart failure. Eur Heart J 2003,24 (abstract suppl):P1027

Thilly N, Briançon S, Juillière Y, Dufay E, Zannad F. Improving angiotensin-converting enzyme inhibitor use in patients hospitalised with systolic heart failure: a cluster randomised controlled trial. Eur Heart J 2003,24 (abstract suppl): P1585

Manhenke C, Orn S, Zannad F, Aarsland T, Dickstein K. Elevated levels of serums of C-terminal telopeptide of type I collagen (ICTP) are associated with increased mortality in patients following complicated acute myocardial infarction. Circulation 2003, 108 (17):689

Djaballah W, Moulin F, Djaballah K, Bourquard D, Olivier P, Dousset B, Zannad F, Marie PY, Karcher G, Bertrand A. Changes in blood markers of fibrosis suggest an enhanced development of myocardial fibrosis in patients showing either exercise ischemia on treatment or transmural necrotic sequels at exercise-SPECT. Eur J Nuclear Med 2003,30:S259

Pitt B, Krum H, Nicolau JC, Cardoso S, Parkhomenko A, Aschermann M, Corbalan R, Zannad F, Bittman R, Kleiman J. The EPHESUS trial: Effect of eplerenone in patients with a baseline history of hypertension. Circulation 2003, 108(17):2727

White HD, Aylward PE, Dalby A, Weaver D, Swedberg K, Zannad F, McMurray JJ, Pfeffer MA. One year mortality, stroke, and myocardial Infarction rates remain high in the elderly despite beta-blockade plus angiotensin-converting-enzyme inhibition, Angiotensin Receptor blockade, or both : the VALIANT trial. Circulation 2003, 108(17):3161

Remme W, Cline C, Cohen Solal A, Hobbs R, Keukelaar K, Lopez Sendon J, Macarie C, McMurray J, Rauch B, Zannad F SHAPE. A pan-european general public heart failure awareness and perception survey. Circulation 2003, 108(17):3150

2004

Waeber B, Andrejak M, Zannad F, Laville M, Duru G, Mourad JJ. Traitement antihypertenseur: comparaison de trois stratégies thérapeutiques actuellement recommandées. Arch Mal Cœur Vaiss 2004, 97(2) :S189

Zannad F. Des grands essais aux recommandations: de l'artère obstruée au muscle sauvé. Arch Mal Cœur Vaiss 2004, 97(2) :C285

Thuillez Ch, Zannad F. Essais cliniques, recommandations et pratiques quotidiennes dans l'HTA. Arch Mal Cœur Vaiss 2004, 97(2):S13

Manhenke CA, Stein O, Zannad F, Aarsaland T, Dickstein K, the OPTIMAAL Trial Study Group. Early serum levels of tissue inhibitor of metalloproteinases-1 but not matrix metalloproteinase-1 are associated with cardiovascular death after complicated myocardial infarction. JACC 2004, 1087-106 (poster)

Zannad F, Ketelslegers JM, Schiffrin EL, Williams G, Garthwaite S, He W, Patni R, Pitt B. The effect of eplerenone on markers of cardiac fibrosis: insights from EPHESUS. JACC 2004, 1108-123

Remme WJ, Cline C, Cohen Solal A, Dietz R, Hobbs R, Keukelaar K, Lopez Sendon J, Macarie C, McMurray J, Opasich C, Rauch B, Ruzyllo W, Zannad F. Inadequate perception of heart failure is associated with underuse of diagnostic and therapeutic strategies in heart failure by the primary care physician: results from SHAPE, a major european survey. JACC 2004, 1145-123

Manhenke CA, Stein O, Zannad F, Aarsland T, Dickstein K, The OPTIMAAL Trial Study Group. Early elevation of C-Terminal telopeptide of type I collagen is highly correlated with 30-day mortality in patients with myocardial infarction regardless of infarct localization. JACC 2004, 826-3

Manhenke C, Orn S, Radauceanu A, Alla F, Zannad F, Dickstein K on behalf of the OPTIMAAL-trial study group. The longitudinal profile of markers of cardiac extracellular matrix turnover in patients following acute myocardial infarction. ESC 2004 (poster) Eur Heart J 2004,25:P3492

>Rochette-Paris M, Bracard S, Anxionnat R, Cordebar R, Zannad F, Picard L. Vieillissement cérébral: intérêt des séquences de diffusion et flair dans l'étude des anomalies de la substance blanche. Journées Française de Radiologie, Paris, 19-23 octobre 2002, Journal de Radiologie 2002,83:1293

Bracard S, Anxionnat R, Kearney-Schwartz A, Virion JM, Zannad F. Leukoaraiosis: Flair and T2 weighted sequences comparison and correlation with neurocognitive status. European Society of Neuroradiology, XXVIII Congress and 12th Advanced Course, Istanbul, Turkey, September 11-13, 2003. Neuroradiology, 2003,45,Suppl 1:S77 P-AB10

Andréjak M, Laville M, Zannad F, Duru G, Mourad JJ. Les trois stratégies thérapeutiques actuellement recommandées ne sont pas équivalentes sur le contrôle tensionnel : analyse de l’étude STRATHE. Arch Mal Cœur Vaiss 2003,96 :60(P102)

Andréjak M, Zannad F, Laville M, Duru G, Mourad JJ, Waeber B, on behalf of STRATHE investigators. Better efficacy of initial low dose combination therapy with Preterax® vs. other strategies in hypertension (STRATHE). Dtsch Med Wochenschr 2003, 128 (suppl.3):S158-S159

Bracard S, Schmitt E, Kearney-Schwartz A, Anxionnat R, Virion JM, Kremer S, Zannad F, Picard L. Leucoaraiose: comparison des séquences T2 et Flair et corrélations avec l'état neurocognitif. XXXI Congrès annuel de la Société Française de Neuroradiologie, 6e Journées de Neuroradiologie de Langue Française, Paris, 15-17 mars 2004, Journal of Neuroradiology,2004,31:P-35 p103

Hanon O, Denolle T, Begasse F, Kearney-Schwartz A, Baguet JP, Girerd X. Au nom du Club des Jeunes Hypertensiologues. Association entre un niveau tensionnel élevé en consultation et le suivi d'un protocole d'automesure. Arch Mal Cœur Vaiss,2003,96:026

Kearney-Schwartz A, Virion JM, Alla F, Zannad F. Matrice extracellulaire et remodelage artériel chez l'hypertendu diabétique de type 2. Arch Mal Cœur Vaiss,2003,96: P37

Zannad F, Kessler M, Grunfeld JP, Thuillez C, Leizorovicz A, Lechat P, Rougemond E, Amellal N. The effects of Fosinopril on cardiovascular morbidity and mortality in haemodialysis patients. The FOSIDIAL study.

Zannad F, Mebazaa A, Cohen Solal A, Juillière Y, Guize L, Alla F, Desnos M, Blin P, Paolozzi L, Rouge P. Contribution of hypertension and preserved left ventricular systolic to acute heart failure : the EFICA study. J Hypertens 2004,22 (suppl 2): P1.388

Zannad F, Pitt B. EPHESUS: evidence for the cardioprotective effects of selective aldosterone blockade. J Hypertens 2004,22 (suppl 2): 8A.1

Andréjak M, Zannad F, Laville M, Duru G, Mourad JJ, Waeber B. Better efficacy in hypertension management with perindopril/indapamide (PER/IND) strategy compared to sequential or step by step strategies. STRATHE study: STRAthegies of Treatment in Hypertension: Evaluation. J Hypertens 2004,22 (suppl 2): S384

Blangy H, Sadoul N, Zannad F, Dousset B, Alla F, Radauceanu A, Aliot E. Serum markers in risk stratification of ICD recipients. Heart Rhythm Journal. Abstract n° 101, session 18, NASPE 2004, May 19-22, San Fransisco USA

Kober L, Maggioni A, McMurray J, Velazquez E, Zelenkofske S, Zannad F, Van de Werf F, Swedberg K. Increased risk of both mortality and morbidity with prior as well as current atrial fibrillation after MI: results of VALIANT. Eur Heart J 2004,25:1429

Zannad F, Kessler M, Grunfeld JP, Thuilliez C, Leizorovicz A, Lechat P, Rougemond E, Amellal N. The effects of fosinopril on cardiovascular morbidity and mortality in haemodialysis patients. The FOSIDIAL study. Eur Heart J 2004,25:P2830

Zannad F, Mebazaa A, Juillière Y, Guize L, Cohen-Solal A, Alla F, Blin P, Paolozzi L. The heterogeneity of acute heart failure. Influence of patients characteristics upon admission and history of CHF before admission on short and long-term survival: the EFICA study. Eur Heart J 2004,25:3757

Zannad F, Mebazaa A, Alla F, Juillière Y, Guize L, Cohen-Solal A, Blin P, Paolozzi L. Pre-admission and 4 week mortality in patients with acute decompensated heart failure: the EFICA study. Eur Heart J 2004,25:P509

Zannad F, Mebazaa A, Cohen-Solal A, Juillière Y, Guize L, Alla F, Blin P, Paolozzi L. Incidence of preserved left ventricular function and determinants of short-term mortality in patients with acute heart failure: the EFICA study. Eur Heart J 2004,25:851

Ketelslegers J, Zannad F, Schriffrin E, Garthwaite S, Patni R, Pitt B. The effect of eplerenone on the cytokine osteopontin in post-MI heart failure: an EPHESUS substudy. Eur Heart J 2004,25:P2912

Rajagopalan S, Zannad F, Radauceanu A, Glazer R, Cheng J, Prescott M, Petitjean H, Pitt B. A multicenter double-blind randomized controlled trial of a statin + angiotensin receptor blockade combination in patients with hypertension and concomitant hyperlipidemia. Circulation 2004, (suppl) 110 (17):III-402

Pitt B, Zannad F. Effect of eplerenone on early mortality in patients with heart failure and left ventricular systolic dysfunction post-myocardial infarction (EPHESUS). 1st European Society of Cardiology, Working Group on Acute Cardiac Care, October 17-20, 2004 in Rome

Zannad F, Pilorget V, Dubroca I, Leclercq F, Habib G, Genes N, Mounier-Vehier C. Tolérance du ramipril, 10 mg chez les patients à haut risque cardio-vasculaire : résultats de l’étude EDIT. Arch Mal Cœur Vaiss 2004,97:P120

Mourad JJ, Waeber B, Zannad F, Laville M, Duru G, Andrejak M. Efficacité d’une plurithérapie IEC/diurétique faiblement dosée (PRETERAX) comme traitement de première intention chez les patients hypertendus de stade II. Arch Mal Cœur Vaiss 2004,97:P127

Moulin F, Radauceanu A, Djaballah W, Dousset B, Alla F, Marie PY, Aliot E, Zannad F. Influence de l’ischémie résiduelle d’effort sur les marqueurs sériques du renouvellement de la matrice extra-cellulaire cardiaque dans la cardiopathie ischémique chronique. Arch Mal Cœur Vaiss 2004,97(II) :PC504

Böhme Ph, Ziegler O, Kreutzer M, Quilliot D, Buemann B, Virion JM and Astrup Arne A. Limits of BMI to define obesity : an european DEXA study of 1967 subjects. 13th European Congress on Obesity, 26 – 29 May, 2004, Prague, Czech Republic

Blangy H, Sadoul N, Zannad F, Dousset B, Alla F, Radauceanu A, Aliot E. Serum markers in risk stratifaction of ICD recipients. Europace 2004 ;6(s1) :1-203 (148-2)

Lewis EF, Velazquez EJ, McMurray JJV, Rouleau JL, Solomon SD, Maggioni AP, Swedberg K, Kober L, White H, Dalby AJ, Francis GS, Pieper KS, Zannad F, Califf RM, Pfeffer MA. Heart failure post-myocardial infarction in the new millenium: how often does it occur, can we predict it, and what are the consequences? J Card Fail 2004;10(suppl):S101

Kober L, Maggioni AP, McMurray JJV, Velazquez EJ, Zelenkofske S, Zannad F, Van de Werf F, Swedberg K. Increased risk of both mortality and morbidity with prior as well as current atrial fibrillation after myocardial infarction: results of VALIANT. J Card Fail 2004;10(suppl):S101

2005

Radauceanu A, Virion JM, Ducki C, Capiaumont J, Li M, Zannad F. Functional capacity as assessed by 6-minute walk test is strongly associated with cardiac fibrosis in patients with chronic heart failure. JACC 2005,45:1161-166

Zannad F. Natriuretic peptides and heart failure. Therapeutic perspectives. Arch Mal Coeur Vaiss 2005,98:C233

Zannad F. Heart Failure: toward which management for what cost? Arch Mal Coeur Vaiss 2005,98:A301

Zannad F. RAAS blockade is there a benefit beyond blood pressure lowering? Arch Mal Coeur Vaiss 2005,98:S407

Zannad F. Ace inhibitors in coronary artery patients. Lessons from clinical trials. Arch Mal Coeur Vaiss 2005,98:S458

Anderson J, Zannad F, Solomon H, Mukherjee R, Patni R, Pitt B. Efficacy of eplerenone in killip class II-III post-AMI patients: Results form EPHESUS. JACC 2005,45:1147-233

Remme W, Zannad F, Rauch B, McMurray J, Cohen-Solal A, Keukelaar K, Boccanelli A, Lopez-Sendon J, Hobbs R, Macarie C, Dietz R, Ruzyllo W, Cline C. Awareness of recommended heart failure management among specialists. Do internists, geriatricians, and cardiologists differ? Results of SHAPE. JACC 2005, 45:1058-183

Boivin JM, Rousseau S, Fay R, Radauceanu A, Zannad F.How much and how properly have french general practitioners implemented home blood pressure monitoring in everyday management of hypertension? MEGAMET Study (MEdecins Généralistes et Auto-MEsure Tensionnelle). Journal of Hypertension 2005,23(2) :P3.28

Radauceanu A, Boivin JM, Ray F, Bernaud C, Dabrowski T, Zannad F. Improving assessment of time-effect profile for antihypertensive drugs: a standardized method for a better estimation of the trough to peak ratio. Fund Clin Pharmacol 2005,19:O38

Van Veldhuisen DJ, Aschermann M, Zannad F, Krum H, Vincent J, Mukherjee R, Pitt B. Eplerenone benefit at 30 days in high-risk subgroups in the EPHESUS trial. Eur J Heart Fail 2005,4(Supp 1):79:353

Zannad F. Managing hypertension: a question of STRATHE. Journal of Hypertension 2005,23(2) :105

Mourad JJ, Waeber B, Zannad F, Laville M, Duru G, Andrejak M. Efficacy of a first-line low-dose ACEI/DIURETIC combination therapy (PRETERAX) in stage II hypertensive patients. Journal of Hypertension 2005,23(2) :P1.332

Bangratz S, Blangy H, Dousset B, Sadoul N, Zannad F, Nippert M, Juillière Y, Selton-Suty C. Relations entre paramètres doppler tissulaire, marqueurs sériques de fibrose cardiaque et troubles du rythme ventriculaire chez les patients atteints de cardiomyopathie dilatée primitive. Arch Mal Cœur Vaiss 2005,98 (3) : 40

Ketelslegers J, Zannad F, Vincent J, Mukherjee R, Rousseau M on behalf of EPHESUS investigators. Effect of neurohormones, cyrokines, and collagen markers on the risk of all-cause mortality: results from the EPHESUS trial. Eur Heart J 2005,26:2765

Remme WJ, McMurray J, Lopez Sendon J, Cohen Solal A, Zannad F, Boccanelli S, Rauch B, Keukelaar K on behalf of the SHAPE Study Group. Between-speciality differences in the management of heart failure in Europe despite evidence-based guidelines – the SHAPE survey. Eur Heart J 2005,26:P1781

Selton-Suty C, Bangratz S, Blangy H, Dousset B, Nippert M, Zannad F, Brembilla-Perrot B, Juillière Y. Relationship between Doppler tissue imaging parameters, serum markers of myocardial fibrosis and ventricular arrhythmias in patients with idiopathic dilated cardiomyopathy. Eur Heart J 2005,26:P1594

2006

Zannad F. Quel est le traitement préventif optimal de l’insuffisance cardiaque chez l’hypertendu? XVIes Journées Européennes de la Société Française de Cardiologie. Arch Mal Cœur Vaiss 2006,99(II) :C364

Zannad F. Insuffisance cardiaque aigue : l’importance du problème. XVIes Journées Européennes de la Société Française de Cardiologie. Arch Mal Cœur Vaiss 2006,99(II) :C706

Boutouyrie P, Perret L, Bozec E, Van Bortel L, Joannides R, Kearney-Schwartz A, Kunz C, Pannier B, Pithois-Merli I, Struijker-Boudier H, Laurent S, Simon T. Le contrôle qualité et la lecture centralisée améliore la reproductibilité de la mesure de l’epaisseur intima media cartidienne : l’étude CASHMERE et le réseau GAMETE. Arch Mal Cœur Vaiss 2005,98 :P54

Blangy H, Sadoul N, Zannad F, Dousset B, Alla F, Radauceanu A, Aliot E. Increased collagen type I/III ratio as predictor of VT in coronary artery disease patients. Europace 2005 ;7(s1) :96 (492)

Fellstrom B, Zannad F, Schmieder R, Holdaas H, Jardine A, Rose H, Wilpshaar W. Effect of rosuvastatin on outcomes in chronic haemodialysis patients – baseline data from the AURORA study. 14th International Symposium on Atherosclerosis, 18-22 June 2006, Rome, July. Atherosclerosis Supplements 2006; 7(3):578 Abs Th-P16:387

Zannad F, Fay R. Blood pressure lowering efficacy of olmesartan relative to other angiotensin II receptor antagonists. An overview of randomized controlled studies. Journal of Hypertension 2006, 24 (suppl 4):P1.2

Zannad F. A continuum of benefits with Coversyl in cardiovascular disease. Journal of Hypertension 2006, 24 (suppl 4):S.4.5

Antkotche A, Marre M, Guerci B, Karalliedde J, Lorand D, Starkie M, Stewart M, Viberti GC, Rosiglitazone Fluid Retention Study Group. Prise en charge de la retention des fluids liée à la rosiglitazone. Diabetes & metabolism 2006, (HS 1), vol 32 : O85

Fournier N, Paul JL, Goudouneche D, Ziegler O, Guerci B. Augmentation des capacités d’efflux du cholestérol cellulaire en période postprandiale chez des femmes obèses insulinorésistantes : un mécanisme compensateur ? Diabetes & metabolism 2006, (HS 1), vol 32 : O26

Dellegrottaglie S, Zannad F, Gillespie B, Zhang X, Finkelstein F, Kiser M, Eisele G, Hinderliter A, Levin N, Cattan V, Sengstock D, Rajagopalan S, Saran R. Plasma Amino-terminal propeptide of procollagen type III (PIIINP) correlates with vascular stiffness in Chronic Kidney Disease (CKD): the Renal Research Institute (RRI)-CKD Study. ASN poster presentation session 2006: #551200

Blangy H, Sadoul N, Zannad F, Dousset B, Fay R, Aliot E. Serum markers in risk stratifaction in ICD recipients after MI. XVIes Journées Européennes de la Société Française de Cardiologie. Arch Mal Cœur Vaiss 2006,99(II) :C409

Guize L, Zannad F, Mebazaa A, Juilliere Y, Cohen-Solal A, Alla F pour les investigateurs de l’étude EFICA. L’œdème aigu du poumon de l’hypertendu : l’étude EFICA. Arch Mal Cœur Vaiss 2006,99(II) :C365

Laurent S, Boutouyrie P, Christin-Maitre S, Gompel A, Jaillon P, Thuillez C, Zannad F, Pithois-Merli I, Simoneau D, Simon T. Deleterious effects of beta-blockers on arterial stiffness and central pulse pressure in postmenopausal women : baseline findings from the CASHMERE trial. 2006, in press (poster AHA)

Kearney-Schwartz A, Benetos A, Lecompte Th, Thornton SN, Lacolley P, Regnault V. Age-dependent increased arterial stiffness is associated with composite changes in pro- and anti-coagulant reactions in subclinical atherosclerosis. Hypertension 2006,48(6):779-779

2007

Zannad F. Understanding acute pulmonary edema in hypertensive patients. Arch Mal Cœur Vaiss 2007, 100 :C336

Simon T, Boutouyrie P, Christine-Maitre S, Gompel A, Laurent S, Thuillez C, Zannad F, Pithois-Merli I, Simoneau D. La durée de la ménopause, l’âge à la ménopause et l’absence d’un THS sont associés à une augmentation de l’épaisseur et la rigidité artérielle : données d’inclusion de l’étude CASHMERE. Arch Mal Cœur Vaiss 2007, 100 :PC688

Laurent S, Boutouyrie P, Christine-Maitre S, Gompel A, Jaillon P, Thuillez C, Zannad F, Pithois-Merli I, Simoneau D, Simon T. Effets délétères des betabloquants sur la rigidité artérielle et la pression pulsée centrale chez les femmes ménopausées : données d’inclusion de l’étude CASHMERE. Arch Mal Cœur Vaiss 2007, 100 :PC 792

Zannad F. Blood pressure lowering, necessary but not suffiscient? Arch Mal Cœur Vaiss 2007, 100 :S536

Zannad F. Place des bloqueurs du SRAA dans la prise en charge du post-IDM. Arch Mal Cœur Vaiss 2007, 100 :S391

Rossignol P, Boutouyrie P, Cambillau M, Mouradian D, Bozec E, Gaussem P, Angles-Cano E, Benetos E, Plouin PF, Chatellier G, Jacob MP. Plasma TIMP-2 levels are correlated with functional and structural properties of the arterial wall. Journal of Hypertension 2007, 25(supp 2),pS9

Simon T, Boutouyrie P, Christin-Maitre S, Gompel A, Jaillon P, Thuillez C, Zannad F, Pithois-Merli I, Simoneau D, Laurent S. Deleterious effects of beta-blockers on arterial stiffness and central pulse pressure in menopausal women : baseline findings from the CASHMERE trial. Fund Clin Pharmacol 2007,21(supp 1):80

Simon T, Boutouyrie P, Christine-Maitre S, Gompel A, Joanides R, Kearney-Schwartz A, Kuntz C, Pannier B, Pornel B, Struijker-Boudier H, Thuillez C, Van Bortel L, Zannad F, Simoneau D, Jaillon P. Carotid IMT and stiffness, aortic stiffness and pulse pressure : association with hormone therapy in postmenopausal women : baseline findings from the CASHMERE trial. Fund Clin Pharmacol 2007,21(supp 1):88

Zannad F. Advantages in clinical practice of first-line combination in diabetic patients. J Hypertens 2007,25(supp 2):pS387

Manhenke C, Orn S, Squire I, Zannad F, Dickstein K. The relationship between N-terminal b-type natriuretic peptide and circulating markers of cardiac remodelling in patients following complicated myocardial infarction. Eur J Heart Fail 2007,6:10-11

Zannad F, Adamopoulos C, Fay R, Ahmed A, Filippatos G, Pitt B. How early should eplerenone be initiated in acute myocardial infarction complicated by heart failure? An analysis of early vs late intiation in the EPHESUS trial. Eur Heart J 2007,28(abstract suppl):52

Ahmed A, Zannad F, Young JB, Waagstein F, White M, Rahimtoola SH. Digoxin and reduction in early mortality in chronic heart failure: insights into the lack of late mortality reduction in the digitalis investigation group trial. Eur Heart J 2007,28(abstract suppl):46-47

Wang NC, Konstam MA, Gheorghiade M, Bechhofer R, Burnett JC, Grinfeld L, Swedberg K, Udelson JE, Cook Th, Ouyang J, Zimmer C, Orlandi C, Maggioni AP, Zannad F, on behalf of the EVEREST investigators. Regional comparison of baseline characteristics in patients hospitalized for acute heart failure with systolic dysfunction. 11th HFSA annual scientific meeting. J Card Fail 2007,13(abstract supp 6):S134 (204)

Wang NC, Zannad F, Konstam MA, Bechhofer R, Gheorghiade M, Burnett JC, Grinfeld L, Swedberg K, Udelson JE, Cook Th, Ouyang J, Zimmer C, Orlandi C, Maggioni AP, on behalf of the EVEREST investigators. The QRS interval predicts mortality and rehospitalization in patients hospitalized with worsening heart failure and systolic dysfunction. 11th HFSA annual scientific meeting, J Card Fail 2007,13(abstract supp 6):S142 (233)

Charbonnel B, Blickle JF, Eschwege E, Scheen AJ, Gautier JF. Etude évaluant les effets à long terme de la rosiglitazone et du gliclazide sur la fonction beta-cellulaire dans le diabète de type 2 : aspects méthodologiques et caractéristiques à l’inclusion. Revue Diabetes & metabolism 2007,33,Supp 1,P324,P1S 121

Zannad F, Wang NC, Konstam MA, Bechhofer R, Gheorghiade M, Burnett JC, Grinfeld L, Swedberg K, Udelson JE, Cook T, Ouyang J, Zimmer C, Orlandi C, Maggioni AP and the EVEREST investigators. Regional differences in baseline characteristics and outcomes in patients hospitalized with worsening heart failure and systolic dysfunction. 11th HFSA annual scientific meeting, J Card Fail 2007,13(abstract supp 6):018

Articles et communications didactiques
1998

Guerci B. Traitement substitutif du diabète de type 1 : présent et futur. 13ème symposium international de diabétologie. Synthèse du 16ème congrès de la Fédération internationale du diabète. Elsevier, 1998, Paris, pp 187-209

Guerci B. Macroangiopathie chez le patient diabétique : épidémiologie, clinique et physiopathologie. 13ème symposium international de diabétologie. Synthèse du 16ème congrès de la Fédération internationale du diabète. Elsevier, 1998, Paris, pp 126-154

2000

Drouin P, Ziegler O, Guerci B. Que peut-on attendre d'un lecteur de glycémies ? Journées de Diabétologie 2000. Flammarion Médecine-Sciences, pp 211-225

2001

Böhme P, Quilliot D, Guerci B, Benamo RE, Virion JM, Drouin P, Ziegler O. Limites de l'absorptiométrie biphotonique à rayons X (DEXA) pour l'étude de la composition corporelle chez le sujet obèse.

Böhme P, Virion JM, Quilliot D, Guerci B, Benamo E, Drouin P, Ziegler O. Quel seuil d'indice de masse corporelle pour définir l'obésité ? 17ème conférence annuelle sur l'Obésité, Paris, 27-28 janvier 2001

Böhme P, Quilliot D, Guerci B, Benamo RE, Virion JM, Drouin P, Ziegler O. Limites de l'absorptiométrie biphotonique à rayons X (DEXA) pour l'étude de la composition corporelle chez le sujet obèse. 17ème conférence annuelle sur l'Obésité, Paris, 27-28 janvier 2001

Böhme P, Virion JM, Quilliot D, Guerci B, Benamo E, Drouin P, Ziegler O. Quel seuil d'indice de masse corporelle pour définir l'obésité ?

2004

Radauceanu A, Zannad F. Evaluation du profil temps-activité et de la durée d’action des antihypertenseurs. Mt Cardiologie, vol.2, n°5-6, septembre-décembre 2004,pp 298-302

2005

Zannad F. Post-Infarctus : faut-il prescrire un bloqueur du système rénnine angiotensine à tous les malades ? Capital Equipement Médical, N°89 – octobre 2005, pp 5

2006

Zannad F. Aldostérone et complications du post-infarctus. Les Journées Françaises de l’Insuffisance Cardiaque. Arch Mal Cœur Vaiss Pratique, nov 2006 :pp 6-8.

Zannad F. Revue critique des grands essais thérapeutiques dans l’hypertension artérielle. Cardinale, Tome XVIII – N° 9, novembre 2006, pp 6-8

2007

Zannad F. Les freins à l’utilisation des bêtabloquants chez les patients hypertendus à risque métabolique : aspects cliniques. AMC pratique, suppl n°157, avril 2007 : pp 9-11

Zannad F. Recommandations sur la prise en charge de l’HTA essentielle de l’adulte. Impact Medecine,202, mai 2007 : pp 35